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ABSTRACT 
 
 Fast scan cyclic voltammetry (FSCV) can be utilized to detect neurotransmitter 
release and uptake in brain slices.  When combining this technique with disease state 
animals models, information for therapeutic targets can be obtained.  Herein, the 
evaluation of stimulated dopamine release and uptake in animal models was used in 
conjunction with pharmacological agents to assess neurological problems caused by 
Fragile X syndrome and chemotherapy.  Fragile X Syndrome, a genetic form of mental 
retardation caused by a trinucleotide repeat expansion, was investigated by combining 
behavioral analysis and FSCV to determine alterations in dopamine release, dopamine 
uptake, effects of amphetamine treatments, and the functionality of the D2 autoreceptor.  
Side effects of chemotherapy can include alteration in neurological function and were 
investigated by using FSCV to monitor for effect on dopamine release and uptake 
patterns in the striatum of rats being dosed with Carboplatin, a chemotherapeutic drug.  
Finally, instrumentation was established to use caged compounds to photo release 
glutamate while collecting FSCV data of dopamine release to evaluate instantaneous 
effects of glutamate on the dopamine system in brain slices.   
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CHAPTER 1 INTRODUCTION 
 
 Understanding the underlying chemical mechanisms of neurological disorders 
and diseases is key to being able to successfully develop therapeutic methods of 
treatment.  It is necessary to be able to study neurological systems without causing 
much disturbance or damage to the system.  Fast scan cyclic voltammetry (FSCV) has 
become a useful method for the measurement of neurochemical release both in vitro 
and in vivo. FSCV has long been used to evaluate dopamine release and uptake in 
brain slices from animal models of disease or altered brain chemistries (1).  When 
pairing FSCV in brain slices with pharmacological agents, such as dopamine transporter 
antagonists or dopamine autoreceptor agonists, information can be obtained about the 
neurological system.  The following sections include an introduction to FSCV, the brain 
dopamine system, the measurement of dopamine release and uptake, and calculating 
dopamine uptake parameters using modeling software.  The work done using the 
application of the FSCV method to evaluate dopamine release and uptake in Fragile X 
syndrome as well as the phenomenon known as “chemobrain” are presented.  Finally, a 
method for the combination of FSCV with photoreleased glutamate to determine 
immediate effects on dopamine release and uptake are discussed.  
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1.1 Electrochemical Methods 
 
1.1.1 Overview of voltammetry   
 Voltammetry is an electroanalytical method that obtains information about an 
analyte by varying the potential applied to an electrode and then detecting the current 
produced by the electrochemical reaction of the analyte at the electrode surface.  
Voltammetry can be used to study various types of analytes and systems including 
inorganic ions and organic molecules in solution.  A major shift in the use of 
voltammetric methods occurred in the early 1970’s as Ralph N. Adams began to use 
voltammetry as a method for evaluating biological amines in vivo, thus opening a new 
field for electrochemical applications in evaluation of biological systems containing 
electroactive molecules(2). 
   In a typical electrochemical system used to collect voltammetric measurements, 
a working electrode, a counter electrode, and a reference electrode are employed, 
Figure 1. The working electrode is the electrode that will have an applied potential that 
will change based on the waveform applied by the potentiostat, thereby causing the 
redox reaction to occur.  The potential of the working electrode is measured versus a 
reference electrode that will have a constant potential.  A counter electrode, made up of 
an inert material, is often used to complete the circuit, but has little to no part in the 
measured redox reaction.  The potentiostat controls the electrical potential between the 
working and reference electrodes at a preset value by forcing the necessary current to 
flow between the working and counter electrodes to maintain the desired potential.   
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Figure 1.  Diagram of a three electrode system.  The working, counter and reference electrodes are 
labled.  A represents an ammeter measuring the current, while V is representative of a voltmeter 
measuring the voltage difference between the reference and working electrodes.   
 
1.1.2 Cyclic Voltammetry 
 Cyclic voltammetry is performed by applying a triangular waveform (Figure 2) to 
the working electrode where the electrode potential is rapidly increased linearly over 
time then decreased to the starting potential.   
 
Figure 2.  Triangular waveform scan from -0.4 V to 1.0 V to -0.4 V. 
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As the potential becomes more positive, the working electrode will become electron 
deficient.  If a suitable electroactive analyte is present, an oxidation reaction will occur at 
the surface of the electrode.  The oxidation reaction will cause a transfer of electrons 
from the molecule being oxidized to the electrode.  This flow of electrons can then be 
measured as a current.  This current, known as the anodic peak current (ipa), will be 
proportional to the amount of analyte at the surface of the electrode.  As the potential is 
scanned back down to the starting point, the working electrode becomes more electron 
rich.  If the oxidation reaction is reversible, a reduction reaction can now occur at the 
surface of the electrode and be detected again as a current, the cathodic peak current 
(ipc), as the electrodes are transferred to the oxidized form of the analyte, regenerating 
the starting analyte.  When the oxidation causes the formation of a different species that 
will not undergo a reduction reaction when the potential is scanned back to the starting 
point, the oxidation reaction is not reversible, however an oxidation potential can still be 
detected.  The potentials at which these current peaks occur as well as the ratio of the 
anodic and cathodic peaks can be used to determine the identity of the analyte.   
 Voltammetry in solutions that have attained a state of equilibrium obeys the 
Nernst Equation (Equation 1) where the reactions occurring are electrochemically 
reversible. 
E = Eo + RT ln CO      Equation 1 
              nF      CR 
       
Where E is the cell potential, Eo is the standard cell potential, CO is the concentration of 
the oxidized species, CR is the concentration of the reduced species, and n is the 
number of electrons involved in the redox reaction. 
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 An electrochemical reaction is considered to be reversible if it meets the following 
conditions.  First, the voltage separation between the anodic and cathodic peaks follows 
Equation 2, 
∆E = Ep,a – Ep,c = 0.059V/n     Equation 2 
Where n is the number of electrons transferred in the reaction.  Figure 3 is a 
representative voltammogram with the cathodic and anodic peaks labeled.   
 
Figure 3.  Depiction of a reversible slow scan cyclic voltammogram of dopamine (3).  Figure modified 
from Ates et al. 2009.  
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However, when using high scan rates the electron transfer rate slows in relation to the 
scan rate.  Due to the inability of the electron transfer to keep up with the fast scan rate 
a higher potential is required to cause the oxidation to happen, thus the oxidation and 
reduction peaks are separated, yet the reaction is still electrochemically reversible (4). 
Another criterion for reversibility is that  there must be symmetry in the voltammogram 
between the peaks (Equation 3) and as shown in Figure 3.   
|ip,a/ip,c| = 1          Equation 3  
This property of reversibility is also dependent on the scan rates used.  The relationship 
between scan rate and the maximum current is described by the Randles-Sevcik 
equation (Equation 4).  
ip = 0.4463 nFAC(nFvD/RT)
1/2      Equation 4 
Where n is the number of electrons involved in the redox reaction, F is Faraday’s 
constant, C is the concentration of the species, D is the diffusional coefficient.   
Increasing the scan rate will also increase the maximum current and has the same 
effect as increasing the rate of diffusion of the oxidized species in the case of DA.  This 
increase in current due to an increase in scan rate is due to an increase in the flux of 
the analytes in the diffusional layer increase number of analyte molecules coming into 
contact with the electrode.  It is also due to this increase in flux that the oxidized species 
diffuses away and is not available in the same concentration at the electrode surface to 
be reduced, leading to a decrease in the peak height of the reduction peak (5).  This 
diffusion causes the reduction peak to be smaller than the oxidation peak and thus the 
ratio of the peaks is not 1, yet the reaction is still reversible, as is the case with DA using 
fast-scan cyclic voltammetry.   
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1.1.3 Fast Scan Cyclic Voltammetry (FSCV) 
 Fast-scan cyclic voltammetry (FSCV)  is a method of voltammetry which utilizes 
high scan rates and can collect data on a sub-second time scale.  In this work a scan 
rate of 300 V/s was utilized using a carbon-fiber microelectrode with a Ag/AgCl 
reference electrode.  A plot of the current changes detected from the oxidation and 
reduction of the analyte versus the potential applied can be generated, creating a cyclic 
voltammogram.  FSCV utilizes microelectrodes due to the temporal resolution and 
beneficial diffusional characteristics which are discussed in section 1.2.1.  The sub-
second time-scale of data collection associated with the high scan rates allows for the 
detection of very quick biological processes.  FSCV also allows for the detection of very 
small changes (nA scale) in current due to the electrode area and based on Equation 
4.  This detection of small currents is also beneficial for biological systems where the 
concentrations of analytes are low (µM) (6). 
As an electrode becomes electron deficient the negative species in the solution 
around the electrode will assemble next to the electrode forming the inner Helmholtz 
layer.  From there a layer of positive charges will be attracted to the negative layer 
forming the outer Helmholtz layer.  Another layer of opposing charges known as the 
Gouy-Chapman layer will form after this and then the bulk of the solution will remain 
heterogeneous (Figure 4).  This is known as the double layer effect.  The double layer 
causes a capacitance current by creating charging currents.  Charging currents cause 
an excess or deficiency of negative charges at the surface of the electrode.  Due to this 
difference in charge layers of opposing charges form that are different than the bulk of 
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the heterogeneous solution.  The charges assemble adjacent to the electrode surface 
within a few hundred angstroms.  By subtraction of the background current, the 
capacitance current is removed from the voltammogram and the result yields a 
voltammogram of the analyte of interest (7).   
 
 
Figure 4.  Depiction of how charges align creating a double layer when a potential is applied to the 
working electrode.  iH represents the inner Helmholtz layer, H represents the outer Helmholtz layer and 
GC is the Gouy-Chapman layer.  Figure based on information found in Bard and Faulkner(18).   
 
1.1.4 Voltammetry in biological systems 
 Voltammetry, when coupled with microelectrodes, provides advantages over 
other means of chemical detection in biological systems.  One popular method for 
biological sampling is microdialysis.  While microdialysis is a powerful analytical 
method, the probes used are on average around 200 µm in diameter, while 
microelectrodes used in voltammetry can range in size from less than 10 µm to 20 µm 
in diameter (7).  Microdialysis is advantageous in that it allows for the sampling of 
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multiple types of neurochemicals  over long periods of time; however, the size of the 
probe may lead to increased tissue damage compared to smaller electrodes (8).  
Moreover, the use of carbon-fiber microelectrodes allows for the measurement of 
neurotransmitter release and uptake on sub-second timescales, compared to minute 
timescales when using microdialysis.    
 
1.2 Microelectrodes 
 
1.2.1 Microelectrodes in FSCV 
 Microelectrodes used in biological measurements have been constructed using a 
variety of configurations, such as cylindrical, disk, ring and spherical, utilizing different 
materials including, but not limited to, carbon fibers, platinum, and gold (9-15).  This 
work has utilized the cylindrical carbon-fiber microelectrode.  The surface properties of 
cylindrical carbon fiber microelectrodes can be easily manipulated with electrochemical 
pretreatments and have been shown to be less prone to surface degradation and 
fouling in tissues than microelectrodes made of metal, thus making them beneficial for 
use in biological applications (16).    
   Carbon-fiber microelectrodes are particularly useful for measuring 
neurotransmitter concentration changes that occur on fast timescales.  Typically, in our 
applications, 10 CVs/s are collected using scan rates of 300 or 400 V/s, however, higher 
scan rates and CV collection rates may be used.  The ability to collect measurements 
with these temporal resolutions is facilitated by the diffusional properties of 
microelectrodes.  The diffusion that occurs around the surface of the microelectrode 
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yields a much greater current density around the electrode in comparison to 
macroelectrodes and is necessary for the analyte to reach the electrode surface and 
undergo an electrochemical reaction at the surface of the electrode.  The diffusion 
occurring around a cylindrical microelectrode occurs in only one dimension, however, in 
the case of cylindrical microelectrodes a “quasi” steady state that follows Equation 5 
occurs (17-18).   
Iqss= 2nFADoCo*/rolnτ    Where  τ= 4Dot/ro
2   Equation 5 
Where n= the number of electrons transferred in the electrochemical reaction, F= Faraday’s constant, Do= 
the diffusional coefficient of the oxidized species, Co*= the concentration of the oxidized species in the 
bulk solution, ro= the radius of the electroactive surface of the electrode, and t= time.   
Analysis of the equation reveals that, due to time being in the denominator of the 
equation, iqss is in a constant decline.  However, time is found in the τ equation and thus 
subject to the logarithmic function and when working in a time scale of seconds, this 
time dependent decline of iqss occurs at a relatively slow rate.   
Another beneficial quality of using microelectrodes is that the low charging 
currents.  The charging current is proportional to the surface area of the electrode, thus 
decreases as the area of the electrode decreases as shown in Equation 6. 
ic  ∝ 1/A       Equation 6 
 
Where ic is the charging current and A is the area of the electrode.  Lowering the 
charging current lowers the amount of noise in the current detection, thus decreasing 
the limit of detection (15).    When a reaction occurring at the electrode surface causes 
a large increase in current, that excess current, when traveling through a resistive 
solution, creates a potential that opposes the applied potential.  This potential is known 
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as the iR drop and can interfere with the data by distortion of the cyclic voltammogram.  
In order to account for the excess current, a counter electrode is used as an electron 
sink in a three electrode system.  Microelectrodes allow for the use of a two electrode 
system, eliminating the need for a counter electrode.  The small surface area and small 
concentration of analyte produces small currents, causing the iR drop to be negligible 
(4, 15).  In the two electrode cell, the working electrode both causes the reaction with 
the analyte to occur by application of a potential from the potentiostat and also detects 
the change in current caused by the redox reaction (4). 
 
1.2.2  Fabrication of cylindrical carbon-fiber microelectrodes 
 Carbon fiber microelectrodes are constructed by aspirating a single carbon fiber 
through a glass capillary tube.  The capillary is then pulled with a glass puller to form a 
glass seal around the carbon fiber.  The carbon fiber is then cut to the desired length 
beyond the glass seal under a microscope using a scalpel (Figure 5).  Once the fibers 
are cut to the appropriate length, the tips of the electrodes are dipped in an epoxy resin.  
By capillary action the resin fills in any gaps in the glass seal around the carbon fiber.  
The excess resin is rinsed off of the fiber with toluene to ensure that no resin remains 
on the surface of the carbon fiber.  The resin is then cured by heat in an oven.   
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Figure 5.  Depiction of a carbon fiber microelectrode tip.  The glass seal is shown around a cylindrical 
carbon fiber which is cut extending beyond the glass seal.   
 
1.2.3  Electrode Calibration 
 Carbon fiber microelectrodes are calibrated in a flow cell to determine their 
response to a specific concentration of analyte.  The potential waveform and all other 
electrochemical parameters that will be used during data collection are used when 
calibrating the electrodes.  Artificial cerebral spinal fluid (aCSF) is continuously flowed 
across the surface of the electrode.  Since FSCV is a background subtracted method, 
the aCSF is allowed to flow for 3 to 5 seconds before introducing the dopamine 
containing solution.  An HPLC injection valve is used to switch the flow solution from 
aCSF to aCSF containing a known concentration of dopamine.  The electrode is 
exposed to the dopamine solution for 5 seconds and then the valve is switched back to 
the plain aCSF.  The peak current from the DA exposure is measured and used to 
determine the nA/µM calibration factor for the electrode.    
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1.2.4  Dopamine detection using FSCV at carbon-fiber microelectrodes 
 Dopamine has been identified as a major catecholamine neurotransmitter that 
plays a role in many important neurologic functions, including locomotor activity (19-20), 
memory (21-22), motivation and reward (23), cognition (24), food intake and 
emotion(21, 25).  Alterations in dopamine release and uptake have been characterized 
in various neurological disorders including a decrease in stimulated release in mice 
models of Huntington’s disease (1), the loss of dopaminergic neurons in both 
postmortem human examinations and animal models of Parkinson’s disease, and post-
mortem analysis of human tissue has revealed high levels of dopamine in schizophrenia 
(26).  The use of voltammetry has allowed for the determination of alterations in 
dopamine responses in the brain with little damage to the system being evaluated (2, 
27-28).   
 Because dopamine readily gives up 2 electrons, it can be easily oxidized.  The 
dopamine-o-quinone that forms from the oxidation reaction can then be converted back 
to dopamine by a reduction reaction.   Using FSCV with a triangular waveform (-0.4 V to 
+1.0 V) and a scan rate of 300 V/s, when the potential applied to the electrode reaches 
+0.6 V the dopamine at the surface of the electrode will lose two electrons and produce 
a detectable current.  As the potential is scanned back down to the starting potential, 
when -0.2 V is reached the dopamine-o-quinone will accept two electrons (Figure 6) 
and thus a dip in current will be detected as the reduction reaction occurs.   
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Figure 6.  Dopamine is oxidized, losing two electrons, to form dopamine-o-quinone.  The dopamine-o-
quinone can then accept two electrons to reform dopamine.   
 
1.3  Dopamine synthesis, release, and uptake 
1.3.1  Dopamine Synthesis and metabolism 
 Dopamine, which does not cross the blood brain barrier, is synthesized in the 
brain from the amino acid precursor tyrosine.  Tyrosine crosses the blood brain barrier 
and is taken up into dopaminergic cells in the brain.  The tyrosine is then converted to 
DOPA by tyrosine hydroxylase.  DOPA decarboxylase then converts DOPA to 
dopamine (Figure 7).  The dopamine can then be packaged into vesicles by the 
vesicular monoamine transporter (VMAT) for release (29-30).    
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Figure 7.  The synthesis of dopamine in the presynaptic terminal. 
 Metabolism of DA can happen both inside the dopaminergic cell and in the 
extracellular space.  Inside of the cell, monoamine oxidase (MAO) can act on the DA 
converting it to 3,4-Dihydroxyphenylacetic acid (DOPAC), which can then be 
transformed to homovanillic acid (HVA) by catechol-O-methyltransferase (COMT) 
(Figure 8).  Extracellularly, a portion of the released DA can be transformed by COMT 
to 3-methoxytyramine (3-MT) which can then be converted to HVA by MAO.  DA can 
also be converted to norepinepherine by dopamine-β-hydroxylase (31). 
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Figure 8.  The metabolism of dopamine and its metabolites.  Where COMT is catechol-O-methyl 
transferase, DβH is dopamine beta hydroxylase and MOA is monoamine oxidase. 
 
1.3.2 Detection of Dopamine and its Metabolites by HPLC 
 HPLC, when paired with an electrochemical detector, can be utilized in the 
separation and detection of electroactive species.  It has been previously used to detect 
DA and its metabolites in samples prepared from brain homogenate (32-33).  Samples 
can be obtained from specific brain regions, in this work the striatum was removed, and 
homogenized to evaluate total DA content in the striatum and compare DA 
concentrations between animal models of neurological diseases to their wildtype 
counterparts.   
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Briefly, the chromatographic separations were carried out isocratically with a 
mobile phase containing 10% organic phase (acetonitrile) and 90% aqueous phase (75 
mM sodium dihydrogen phosphate monohydrate, 100 µL/L triethylamine, 25 µM EDTA 
tetrasodium tetrahydrate and 1.7 mM 1-octanesulfonic acid sodium salt) at a flow rate of 
0.4 mL/min.  The column used for compound separation was a C 18 column, utilizing 
reverse phase chromatography allowing the separation to occur based on molecular 
polarity where the most polar molecules are eluted first.  A calibration standard 
chromatogram is shown in Figure 9 indicating good separation and detection of 
norepinephrine (NE), DHBA (the internal standard), DOPAC, DA and homovanillic acid 
(HVA).   
 
Figure 9.  HPLC chromatogram of a calibration standard for the quantification of DA and its metabolites 
in the striatum of mice. 
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1.3.3  Dopamine release 
1.3.3.1 The synapse 
 The synapse is the junction formed between two neurons and is the site at which 
neurotransmitters are released and communications between the two cell bodies takes 
place.  The release of neurotransmitters from the presynaptic terminal occurs with the 
depolarization of the terminal due to an action potential.  When neurotransmitters are 
released they can either act on the presynaptic receptors, cross to the postsynaptic 
terminal where they can act on postsynaptic receptors, be taken back into the 
presynaptic terminal by a transmitter specific transporter, or can diffuse out of the 
synaptic cleft to act on receptors on other neurons.   
 
1.3.3.2  Vesicular release 
 Neurotransmitter release occurs by exocytosis of synaptic vesicles at the 
membrane surface of the synapse.  After DA is synthesized in the presynaptic terminal 
it is packaged into vesicles by VMAT2, the neuronal vesicular monoamine transporter.  
The vesicles near the surface of the synaptic membrane, considered the active zone, 
then undergo docking and priming, preparing them for an action potential that will cause 
them to release their contents into the synaptic cleft.  When an action potential occurs, 
voltage-gated Ca2+ channels are opened and the neurotransmitters are released by 
fusion of the vesicular membrane with the neuronal membrane, followed by endocytosis 
of the vesicle. (34).   
 Three different modes or vesicular recycling have been observed in single cell 
preparations (35).  The first and fastest mode has been termed “kiss and run” in which 
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the vesicle quickly binds, releases its contents and is quickly retrieved from the 
membrane to be recycled, occurring on a time scale between 400 and 860 ms.  The 
second type, compensatory, takes between 10 to 30 seconds for the fusion and 
recycling of the vesicle to occur.  The third mode of recycling, stranded, occurs when 
the vesicle fuses and releases its contents, but remains attached to the membrane until 
another action potential occurs.  DA has been shown to be released under all three of 
the mentioned modes of vesicular release and recycling (36). 
 
Figure 10.  Vesicular release of DA into the extracellular space.  1.  DA is packaged into vesicles by 
VMAT2, the vesicular monoamine transporter, which then become a part the vesicles ready for release 
(2).  3. The vesicles then dock with the membrane and are primed.  4.  After in influx of Ca
2+
 the 
exocytosis of DA occurs.  The vesicle then separates from the membrane and is recycled back (5) to be 
refilled with DA.   
 
 20
 Vesicles have been classified as being a part of three distinct categories: the 
readily releasable pool (RRP), the recycling pool and the reserve pool (37-40).  The 
RRP consists of the vesicles that are near the synaptic membrane and exocytose upon 
mild stimulation.  The recycling pool is made up of those vesicles that will replace the 
RRP after exocytosis.  The reserve pool vesicles, the largest pool in the presynaptic 
terminal, is only mobilized after long periods of synaptic activity (41). 
 
Figure 11.  The three pools of DA.  The most abundant pool is the reserve pool, however it takes intense 
stimulation to activate this pool.    
 
1.3.4 Neurotransmitter diffusion 
 Most neurotransmission occurs within the synaptic cleft between the presynaptic 
and postsynaptic terminals where the released neurotransmitter acts upon the receptors 
within that cleft.  DA transmission in the striatum has been shown to diffuse outside of 
the synaptic cleft of release and acts upon other target receptors distances of over 12 
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µm away (42-44).  The ability of DA to diffuse outside of the synaptic cleft allows DA to 
cause an effect on a much larger number of target cells.     
 
Figure 12.  Simplification of the diffusion of DA in the synaptic cleft after vesicular release.  DA can be 
taken up back into the presynaptic terminal by the DA transporter, it can diffuse to one of the DA 
receptors or it can diffuse out of the synaptic cleft. 
 
1.3.5  Dopamine Receptors 
 Dopamine receptors were classified into two categories when discovered.  These 
groups are now known as D1-like and D2-like. The DA receptors are G protein-coupled 
metabotropic receptors that primarily function through affecting cyclic adenosine 
monophosphate (cAMP) levels (25).  The D1-like receptors, which include the D1 and 
D5 receptors, increase cAMP levels by increasing adenylyl cyclase (AC) activity, while 
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the activation of D2-like receptors, including D2, D3 and D4 receptors cause a decrease 
in cAMP by inhibition of AC.   
 The activity of the D2 receptor is of particular interest when it comes to regulation 
of DA release in DA neurons.  Activation of the D2 receptor has been shown to 
decrease DA release (45-48).  The stimulation of presynaptic D2 receptors causes a 
feedback mechanism that lowers DA levels by inhibiting DA synthesis and release (49-
50).  The D2 receptor agonist quinpirole has been shown to deplete stimulated DA 
release in the striatum (51). 
Table 1.  Dopamine Receptors and their functions (25, 48, 52-58). 
 
D1-Like 
 
D1 
Stimulatory effect – activates adenylyl cyclase 
Most abundant DA receptor 
Regulates D2 responses 
Predominately postsynaptic 
D5 
Stimulatory effect – activates adenylyl cyclase 
Expressed in limbic regions 
Predominately postsynaptic 
 
 
 
 
D2-Like 
 
D2 
Regulate DA release by inhibiting DA synthesis, 
storage and release 
Autoreceptor for Dopamine 
Presynaptic and postsynaptic receptor 
 
D3 
Inhibits adenylyl cyclase 
Postsynaptic receptor 
Possible autoreceptor 
D4 Function not well characterized 
 
1.3.6  Dopamine Transporter (DAT) 
 The dopamine transporter (DAT) is a transmembrane protein located on the 
plasma membrane of the presynaptic nerve terminal to transport extracellular DA into 
the neuron from the extracellular space.  DAT is a key element in termination of 
neurotransmission by DA by removing it from the extracellular space where it can act on 
DA receptors (59-61).  DAT is made up of 12 transmembrane domains with alternating 
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extracellular and intracellular loops with both the C- and N- terminus located inside the 
cell.  The transporter is Na+/Cl- dependant, requiring a sodium ion to bind extracellularly 
in order for DA to bind and the transporter to undergo a conformational change and 
move both the sodium and dopamine into the intracellular space (62). 
 
1.4  Measuring Dopamine Release and Uptake in Brain Slices 
1.4.1  Neuroanatomy 
 The area of dopaminergic activity of interest in this work is the Caudate-Putamen 
(CPu), also known as the striatum.  The CPu receives a substantial amount of 
dopaminergic input from two distinct populations of DA neurons, the dorsal tier neurons 
and the ventral tier neurons (Figure 13).  The dorsal tier neurons have their cell bodies 
located in the dorsal substantia nigra pars compacta (SNc), while the ventral tier neuron 
cell bodies are located in the ventral SNc (63).  These neurons extending from the SNc 
to the CPu maintain their topographical pattern between the two regions (64-65).  These 
projections of neurons that begin in the SNc and terminate in the CPu are known as the 
nigrostriatal pathway.  The nigrostriatal pathway is involved in motor control by 
involvement in the basal ganglia loop and it is the destruction of the nigrostriatal 
pathway that plays a major role in causing Parkinson’s disease and the loss of motor 
control associated with the disease (64).   
 Movement is triggered from the SNc by the nigrostriatal pathway causing 
activation of DA receptors in the striatum.  The activation of these receptors is 
fundamental in maintaining normal posture and the origin of normal movements (58).   A 
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loss of DA activity in the striatum has been shown in both Huntington’s chorea and in 
Parkinson’s disease (1, 66).   
 
Figure 13.  Depiction of the substantia nigra pathway in a mouse brain.  Dopamine neurons project from 
the substantia nigra to the caudate putamen. 
 
1.4.2  Brain Slices 
 Brain slices have long been accepted as an appropriate method of evaluation of 
neurobiology and activity (67-69).  By perfusion with artificial cerebral spinal fluid, slices 
made from brain tissue can be kept functioning (27, 70).  There are several advantages 
associated with performing experiments in vitro as opposed to in vivo.  Drugs can be 
applied directly to the slices by perfusion, thus allowing the effects of specific 
concentrations to be evaluated.  It is also advantageous to be able to visually place 
electrodes in specific locations when performing voltammetry experiments and to be 
able to move the electrodes to various locations with little damage to the tissue.     
 
1.4.3  Pharmacological Agents that Alter Release and Uptake 
 Pharmacological agents that alter DA release and uptake can be used to 
evaluate neurological diseases and disorders in FSCV brain slice experiments.  Some 
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of the common drugs used include amphetamine and cocaine.  Other Drugs used in this 
study include GBR 12909, quinpirole and alpha-methyl-p-tyrosine (αMPT). 
 Amphetamine (AMPH), a psychostimulant commonly used for the treatment of 
attention deficit, narcolepsy and obesity, was first synthesized in 1887 by Lazar 
Edeleanu.  The stimulating effects of the drug were not known until 1910 when it was 
tested in animals by Gordon Alles who was searching for a decongestant (71).  The 
stimulating effects of AMPH have been shown to be due to the release of 
catecholamines caused by AMPH working by two mechanisms.  First, AMPH causes 
excess DA to be released into the extracelluar space by binding to DAT and reversing 
its orientation, allowing outward transport of DA (72-74).  AMPH also crosses through 
the plasma membrane by lipophilic diffusion (74-76).  Once inside of the synapse, 
AMPH causes the depletion of vesicular DA by binding interaction with VMAT2, causing 
more extracellular DA, which can be outwardly transported by DAT (77).   
 Cocaine, an addictive stimulant found in the leaves of the coca plant, has been 
shown to bind to DAT and inhibit DA uptake, thus increasing extracellular levels of DA 
and causing a stimulating effect (61, 78-80).   It has also been shown that cocaine can 
affect DA release by activating synapsin dependant reserve pools of DA (81).  Once DA 
synthesis has been halted and its release depleted, administration of cocaine can 
restore DA release.  
 GBR 12909 has been shown to be a highly selective DAT inhibitor, thus 
effectively blocking presynaptic DA uptake (82).  Because of the selectivity of GBR 
12909 for DAT, it is advantageous to use it as a DAT inhibitor over cocaine and AMPH, 
both of which will act on transporters for different monoamines as well as DAT (83).    
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 Activation of the D2 autoreceptor provides a negative feedback mechanism 
inhibiting adenylyl cyclase activity, halting DA synthesis and thus diminishing DA 
release and uptake (84).  This mechanism of action prevents too much DA from being 
released into the extracellular space.  Quinpirole, a D2 agonist, has been shown to 
activate the D2 autoreceptor and inhibit DA release in the striatum (85).   
 DA release can also be altered by preventing the synthesis of DA in the 
presynaptic terminal.  Alpha-methyl-para-tyrosine is a tyrosine hydroxylase inhibitor 
(86).  Tyrosine hydroxylase is involved in the production of DA.  Once it is function is 
inhibited, tyrosine is no longer converted to L-DOPA which is a precursor of DA.  Thus 
the synthesis of DA is halted and its packaging and release will be diminished. 
 
1.4.4  Modeling Stimulated Release Plots 
 Dopamine uptake has been shown to follow Michaelis-Menten kinetics (27, 87-
88).  Based on previous experiments, equation 7 is accepted (89): 
        Equation 7 
where (DA)o is extracellular DA, T is the DA transporter and (DA)I is intracellular DA. 
where (DA)o is extracellular DA, T is the dopamine transporter and (DA)I is intracellular 
DA. The Michaelis-Menten kinetic behavior of the DAT allows us to model the raw data 
to obtain information about [DA]p, Vmax and KM, where [DA]p is the peak DA release 
corrected for electrode performance and uptake, Vmax is the maximum rate of DA uptake 
and is proportional to the number of DAT molecules, and KM is the concentration of DA 
at ½ Vmax and is considered a measure of the affinity of DA for DAT.  In the absence of 
drugs, the accepted value for KM is 0.2 µM (87, 90) which allows us to use modeling 
(DA)o + T (DA)T (DA)i + T
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software, developed by the Wightman group at the University of North Carolina, to then 
determine [DA]p and Vmax based on Equation 8.   
  d[DA]/dt = [DA]p – Vmax/(KM/[DA] + 1)    Equation 8 
Figure 12 shows our experimentally collected data, the black dots, and the model fit to 
our data, the red line.  By adjusting the value of [DA]p in the software, the height of the 
model curve changes to fit the experimental data.  By adjusting the Vmax values in the 
software, the width of the curve changes to fit to the data and thus we can obtain a good 
fit to the curve.  When a slice is exposed to a drug such as AMPH, which alters the 
uptake, the experimentally determined Vmax in the absence of drug is used in the 
software and the value of KM is adjusted to obtain a good fit to the data.   
 
Figure 14. Modeling raw data.  The experimentally collected data is shown by the black dots, the arrow 
indicates a stimulus pulse and the red line is the model fit curve to the data.   
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1.4.5  Competitive Inhibition 
In the presence of a competitive inhibitor, I , the inhibition constant Ki can be 
determined.  In the case of a competitive inhibitor the following is also occurring: 
        Equation 9 
where Ki is the dissociation constant and follows Equation 10. 
 Ki = [I][T]/[IT]      Equation 10 
In this situation we can plot (KM)app vs. [I], where (KM)app is defined as KM(1 + [I]/Ki), and 
obtain a linear plot with a slope of KM/Ki (89).  In competitive inhibition, Vmax remains 
unchanged due to the inhibitor binding, in most cases, to the same location as the 
substrate and increasing the concentration of the substrate can overcome the inhibition.  
KM changes in competitive inhibition because the concentration of substrate needed to 
reach Vmax has increased, thus shifting the value of KM (Figure 15).   
 
Figure 15.  Representation of enzyme rates.  The black line represents no inhibitor present, while the red 
line represents competitive inhibition.  In competitive inhibition, Vmax is unchanged, yet KM increases due 
to a higher concentration of substrate being required to reach Vmax. 
I + T IT
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1.5  The Force-Plate Actometer 
 The force-plate actometer was developed by Professor S.C. Fowler of the 
University of Kansas, has been well established for monitoring animal behavior 
including:  locomotion, tremor, special patterning and focused stereotypy (91).  The 
force-plate actometer consists of a plate with four transducers located under each 
corner with a cage over the plate but not touch it.  The movement of the animal can then 
be traced in x and y directions as the animal move about the plate, as well as the z 
direction, detecting vertical force variation.  The ability to monitor the vertical 
movements of the animal is important when evaluating focused stereotypy due to a 
decrease in locomotion that occurs while the animal experiences movement in the 
vertical direction.  Thus, the force-plate actometer can evaluate focused-stereotypy and 
not mistake it for periods of paralysis.  
  
Figure 16.  Coordinate system of the force plate actometer. 
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To track behavior the force-plate actometer has a transducer under each corner 
of the plate.  To describe the different areas and transducers, the plate can be thought 
of as having four quadrants, each with a transducer in the corner given by their X,Y 
location , as shown in Figure 16.  A 200 gram weight placed in the center of the plate 
will result in the detection of an equal distribution of forces over the transducers as 
shown in Figure 17A.  When the weight is moved to a different location, the distribution 
of forces changes as seen in Figure 17B.  Thus position of the object on the force-plate 
determines the force (f) detected at each corner of the plate.   
 
50
50
50
50
30 100
20 50
A B
 
Figure 17.  (A) The force plate actometer with an object in the center detecting an equal distribution of 
forces across the four transducers, located at the corners of the plate.  (B) The change in forces detected 
once the object moves. 
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By Equations 11 and 12, the location of the object can be determined and thus 
tracked over time and its locomotor activity mapped out as shown in Figure 18. 
x = (X1f1 + X2f2 + X3f3 + X4f4)/(f1 + f2 + f3 + f4)                     Equation 11 
y = (Y1f1 + Y2f2 + Y3f3 + Y4f4)/(f1 + f2 + f3 + f4)                     Equation 12 
 
 
Figure 18.  Depiction of the type of locomotor pattern around the plate of an animal after an actometer 
recording session and the determination of animal movement based on the changes of force distributions.   
 
By recording the force measurements at a high rate over time the rhythmic variations in 
the animal’s movement can also be detected and not just the locomotion (91).  Since 
force measurements are being collected as opposed to position measurements, the 
rhythmic force variations caused by behaviors such as jumping, tremors or stereotypies 
can be detected.  By use of Fourier transform these patterns of vertical frequency 
changes are detected as shown in Figure 19.   
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Figure 19.  The use of Fourier Transform to detect rhythmic patterns in the force data.  The power 
spectrum here represents the focused stereotypy behavior.   
 
Amphetamine-induced focused stereotypy was evaluated in this work utilizing the 
force plate actometer.  In order to compare the focused stereotypy occurring between 
the different genotypes the focused stereotypy scores (FSS) were calculated.  The  
FSS, which is based on the amount of time and the force variance in the z direction as 
well as the number of sectors used,  was determined for the animals based on 
Equation 13 to assess the response to AMPH (92).   
 Focused Stereotypy Score = Σ(%time x Fz variance)  Equation 13 
           # of sectors used 
 
In this work, fast-scan cyclic voltammetry at carbon-fiber microelectrodes (FSCV) 
was used to investigate the electrically-evoked release and uptake of DA in striatal brain 
slices taken from Fmr1 KO mice and WT mice.  These neurochemical measurements 
were compared with behavioral measurements of locomotion and focused stereotypy 
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obtained using a force-plate actometer, a behavioral device that measures variation in 
behavior-induced reactive forces even while the subject is not locomoting (91).  
 
1.6  Summary of subsequent chapters 
 Chapter 2 describes the use of FSCV in the evaluation dopamine release in 
Fragile X Syndrome through the use of Fmr1 knockout mice.   Behavioral analyses were 
performed using a force-plate actometer.  The release and uptake of dopamine was 
characterized in three different age groups.  Pharmacological agents were also 
employed to assess the functionality of the dopamine transporter, the D2 autoreceptor 
and dopamine reserve pools.  These studies revealed information about how alterations 
in the dopamine system in Fragile X syndrome may impact the behavioral phenotype in 
Fmr1 KO mice.   
 Chapter 3 describes our evaluation of the effects of chemotherapy on striatal 
dopamine release.  Many cancer patients report a significant decline in cognitive skills 
after chemotherapy.  Male Wistar rats were dosed with carboplatin as an animal model 
for the examination of the role of dopamine in the Chemobrain phenomena.  Healthy 
male rats were used in order to eliminate any hormonal effect or effect due to the 
cancerous cells on their neurochemistry.  Fast scan cyclic voltammetry was used to 
characterize dopamine release and uptake in the striatum of the rats.  Dopamine 
reserve pools were also evaluated using amphetamine induced dopamine efflux after 
inhibition of dopamine synthesis and depletion of the readily releasable and recycling 
pools of dopamine by electrical stimulation.    
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 Chapter 4 introduces the experimental design and instrumentation for the 
assessment of immediate dopamine release alterations caused by the photorelease of 
caged compounds.  Using caged compounds to evaluate dopamine responses in brain 
slices gives us the ability to introduce a biologically active molecule that is bound to a 
photoprotecting group, which yields the molecule inactive until photolysis removes the 
cage and reforms the biologically active compound.  The design and setup of the 
instrumentation are presented with a brief introduction to its potential use in brain slices.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 35
1.7  References 
1. Johnson, M. A., Rajan, V., Miller, C. E., and Wightman, R. M. (2006) Dopamine 
release is severely compromised in the R6/2 mouse model of Huntington's 
disease, Journal of Neurochemistry 97, 737-746. 
 
2. Kissinger, P. T., Hart, J. B., and Adams, R. N. (1973) Voltammetry in brain 
tissue--a new neurophysiological measurement, Brain Res 55, 209-213. 
 
3. Ates, M., Sarac, A. S., Turhan, C. M., and Ayaz, N. E. (2009) Polycarbazole 
modified carbon fiber microelectrode: Surface characterization and dopamine 
sensor, Fibers and Polymers 10, 46-52. 
 
4. Bond, A. M. (2002) Broadening Electrochemical Horizons:  Principles and 
Illistration of Voltammetric and Related Techniques, Oxford University Press, 
New York. 
 
5. Gosser Jr, D. K. (1994) Cyclic Voltammetry Simulation and Analysis of Reaction 
Mechanisms, VCH Publishers Inc., New York. 
 
6. Stamford, J. A., Kruk, Z. L., Millar, J., and Wightman, R. M. (1984) Striatal 
dopamine uptake in the rat - invivo analysis by fast cyclic voltammetry, 
Neuroscience Letters 51, 133-138. 
 
7. Kawagoe, K. T., Zimmerman, J. B., and Wightman, R. M. (1993) Principles of 
Voltammetry and Microelectrode Surface-States, Journal of Neuroscience 
Methods 48, 225-240. 
 
8. Stenken, J. A., Church, M. K., Gill, C. A., and Clough, G. F. (2010) How 
Minimally Invasive is Microdialysis Sampling? A Cautionary Note for Cytokine 
Collection in Human Skin and other Clinical Studies, Aaps J. 12, 73-78. 
 
9. Authier, L., Grossiord, C., Brossier, P., and Limoges, B. (2001) Gold 
nanoparticle-based quantitative electrochemical detection of amplified human 
cytomegalovirus DNA using disposable microband electrodes, Analytical 
Chemistry 73, 4450-4456. 
 
10. Conyers, J. L., and White, H. S. (2000) Electrochemical characterization of 
electrodes with submicrometer dimensions, Analytical Chemistry 72, 4441-4446. 
 
11. Demaille, C., Brust, M., Tsionsky, M., and Bard, A. J. (1997) Fabrication and 
characterization of self-assembled spherical gold ultramicroelectrodes, Analytical 
Chemistry 69, 2323-2328. 
 
12. Katemann, B. B., and Schuhmann, T. (2002) Fabrication and characterization of 
needle-type Pt-disk nanoelectrodes, Electroanalysis 14, 22-28. 
 36
 
13. Menon, V. P., and Martin, C. R. (1995) Fabrication and evaluation of 
nanoelectrode ensembles, Analytical Chemistry 67, 1920-1928. 
 
14. Slevin, C. J., Gray, N. J., Macpherson, J. V., Webb, M. A., and Unwin, P. R. 
(1999) Fabrication and characterisation of nanometre-sized platinum electrodes 
for voltammetric analysis and imaging, Electrochemistry Communications 1, 282-
288. 
 
15. Kissinger, P. T., and Heineman, W. R., (Eds.) (1996) Laboratory Techniques in 
Electroanalytica Chemistry, 2nd ed., Marcel Dekker, Inc., New York. 
 
16. Kovach, P. M., Ewing, A. G., Wilson, R. L., and Wightman, R. M. (1984) Invitro 
comparison of the selectivity of electrodes for invivo electrochemistry, Journal of 
Neuroscience Methods 10, 215-227. 
 
17. Bard, A. J., Abruna, H. D., Chidsey, C. E., Faulkner, L. R., Feldberg, S. W., Itaya, 
K., Majda, M., Melroy, O., Murray, R. W., Porter, M. D., Soriaga, M. P., and 
White, H. S. (1993) The electrode-electrolyte interface - a status-report, J. Phys. 
Chem. 97, 7147-7173. 
 
18. Bard, A. J., and Faulkner, L. R. (2001) Electrochemical Methods:  Fundamentals 
and Applications, John Wiley & Sons. 
 
19. Beninger, R. J. (1983) The role of dopamine in locomotor-activity and learning, 
Brain Research Reviews 6, 173-196. 
 
20. Pijnenburg, A. J. J., Honig, W. M. M., Vanderheyden, J. A. M., and Vanrossum, 
J. M. (1976) Effects of chemical stimulation of mesolimbic dopamine system 
upon locomotor activity, European Journal of Pharmacology 35, 45-58. 
 
21. Berke, J. D., and Hyman, S. E. (2000) Addiction, dopamine, and the molecular 
mechanisms of memory, Neuron 25, 515-532. 
 
22. Williams, G. V., and Goldmanrakic, P. S. (1995) Modulation of memory fields by 
dopamine D1 receptors in prefrontal cortex, Nature 376, 572-575. 
 
23. Wise, R. A. (2004) Dopamine, learning and motivation, Nature Reviews 
Neuroscience 5, 483-494. 
 
24. Everitt, B. J., and Robbins, T. W. (1997) Central cholinergic systems and 
cognition, Annual Review of Psychology 48, 649-684. 
 
25. Missale, C., Nash, S. R., Robinson, S. W., Jaber, M., and Caron, M. G. (1998) 
Dopamine receptors: From structure to function, Physiological Reviews 78, 189-
225. 
 37
 
26. Davis, K. L., Kahn, R. S., Ko, G., and Davidson, M. (1991) Dopamine in 
schizophrenia - a review and reconceptualization, Am. J. Psychiat. 148, 1474-
1486. 
 
27. Wightman, R. M., Amatore, C., Engstrom, R. C., Hale, P. D., Kristensen, E. W., 
Kuhr, W. G., and May, L. J. (1988) Real-Time Characterization of Dopamine 
Overflow and Uptake in the Rat Striatum, Neuroscience 25, 513-523. 
 
28. Wightman, R. M., Strope, E., Plotsky, P., and Adams, R. N. (1978) Invivo 
voltammetry - monitoring of dopamine metabolites in csf following release by 
electrical-stimulation, Brain Research 159, 55-68. 
 
29. Cartier, E. A., Parra, L. A., Baust, T. B., Quiroz, M., Salazar, G., Faundez, V., 
Egana, L., and Torres, G. E. (2010) A Biochemical and Functional Protein 
Complex Involving Dopamine Synthesis and Transport into Synaptic Vesicles, J. 
Biol. Chem. 285, 1957-1966. 
 
30. Izumi, Y., Yamamoto, N., Kume, T., Katsuki, H., Sawada, H., and Akaike, A. 
(2008) Regulation of intracellular dopamine levels by dopaminergic drugs: 
Involvement of vesicular monoamine transporter, European Journal of 
Pharmacology 582, 52-61. 
 
31. Qi, Z., Miller, G. W., and Voit, E. O. (2008) Computational Systems Analysis of 
Dopamine Metabolism, Plos One 3. 
 
32. Fulks, J. L., O'Bryhim, B. E., Wenzel, S. K., Fowler, S. C., Vorontsova, E., 
Pinkston, J. W., Ortiz, A. N., and Johnson, M. A. (2010) Dopamine Release and 
Uptake Impairments and Behavioral Alterations Observed in Mice that Model 
Fragile X Mental Retardation Syndrome, ACS Chemical Neuroscience 1, 679-
690. 
 
33. Bailey, B. (2006) Monoamines and Acid Metabolites Analysis for Tissue 
Samples, Magellan Biosciences, esa Magellan Biosciences. 
 
34. Sudhof, T. C. (2004) The synaptic vesicle cycle, Annual Review of Neuroscience 
27, 509-547. 
 
35. Gandhi, S. P., and Stevens, C. F. (2003) Three modes of synaptic vesicular 
recycling revealed by single-vesicle imaging, Nature 423, 607-613. 
 
36. Staal, R. G. W., Mosharov, E. V., and Sulzer, D. (2004) Dopamine neurons 
release transmitter via a flickering fusion pore, Nat. Neurosci. 7, 341-346. 
 
37. Murthy, V. N., and Stevens, C. F. (1999) Reversal of synaptic vesicle docking at 
central synapses, Nat. Neurosci. 2, 503-507. 
 38
 
38. Neves, G., and Lagnado, L. (1999) The kinetics of exocytosis and endocytosis in 
the synaptic terminal of goldfish retinal bipolar cells, Journal of Physiology-
London 515, 181-202. 
 
39. Rizzoli, S. O., and Betz, W. J. (2005) Synaptic vesicle pools, Nature Reviews 
Neuroscience 6, 57-69. 
 
40. Zucker, R. S., and Regehr, W. G. (2002) Short-term synaptic plasticity, Annual 
Review of Physiology 64, 355-405. 
 
41. Stevens, C. F., and Tsujimoto, T. (1995) Estimates for the pool size of releasable 
quanta at a single central synapse and for the time required to refill the pool, 
Proceedings of the National Academy of Sciences of the United States of 
America 92, 846-849. 
 
42. Borland, L. M., Shi, G. Y., Yang, H., and Michael, A. C. (2005) Voltammetric 
study of extracellular dopamine near microdialysis probes acutely implanted in 
the striatum of the anesthetized rat, Journal of Neuroscience Methods 146, 149-
158. 
 
43. Gonon, F. (1997) Prolonged and extrasynaptic excitatory action of dopamine 
mediated by D1 receptors in the rat striatum in vivo, Journal of Neuroscience 17, 
5972-5978. 
 
44. Zoli, M., Torri, C., Ferrari, R., Jansson, A., Zini, I., Fuxe, K., and Agnati, L. F. 
(1998) The emergence of the volume transmission concept, Brain Research 
Reviews 26, 136-147. 
 
45. Gonon, F. G., and Buda, M. J. (1985) Regulation of dopamine release by impulse 
flow and by autoreceptors as studied by invivo voltammetry in the rat striatum, 
Neuroscience 14, 765-774. 
 
46. Jomphe, C., Tiberi, M., and Trudeau, L. E. (2006) Expression of D2 receptor 
isoforms in cultured neurons reveals equipotent autoreceptor function, 
Neuropharmacology 50, 595-605. 
 
47. Starke, K., Gothert, M., and Kilbinger, H. (1989) Modulation of neurotransmitter 
release by presynaptic autoreceptors, Physiological Reviews 69, 864-989. 
 
48. Tepper, J. M., Sun, B. C., Martin, L. P., and Creese, I. (1997) Functional roles of 
dopamine D-2 and D-3 autoreceptors on nigrostriatal neurons analyzed by 
antisense knockdown in vivo, Journal of Neuroscience 17, 2519-2530. 
 
 39
49. Benkert, O., Grunder, G., and Wetzel, H. (1992) Dopamine autoreceptor agonists 
in the treatment of schizophrenia and major depression, Pharmacopsychiatry 25, 
254-260. 
 
50. Sokoloff, P., Giros, B., Martres, M. P., Bouthenet, M. L., and Schwartz, J. C. 
(1990) Molecular-cloning and characterization of a novel dopamine receptor (D3) 
as a target for neuroleptics, Nature 347, 146-151. 
 
51. Maina, F. K., and Mathews, T. A. (2010) Functional Fast Scan Cyclic 
Voltammetry Assay to Characterize Dopamine D2 and D3 Autoreceptors in the 
Mouse Striatum, Acs Chemical Neuroscience 1, 450-462. 
 
52. Beaulieu, J. M., and Gainetdinov, R. R. (2011) The Physiology, Signaling, and 
Pharmacology of Dopamine Receptors, Pharmacological Reviews 63, 182-217. 
 
53. Clark, D., Hjorth, S., and Carlsson, A. (1985) Dopamine receptor agonists - 
mechanisms underlying autoreceptor selectivity .2. theoretical considerations, 
Journal of Neural Transmission 62, 171-207. 
 
54. Seeman, P. (1980) Brain dopamine-receptors, Pharmacological Reviews 32, 
229-313. 
 
55. Seeman, P., and Tallerico, T. (2003) Link between dopamine D-1 and D-2 
receptors in rat and human striatal tissues, Synapse 47, 250-254. 
 
56. Seeman, P., Tallerico, T., and Ko, F. (2003) Dopamine displaces H-3 
domperidone from high-affinity sites of the dopamine D2 receptor, but not H-3 
raclopride or H-3 spiperone in isotonic medium: Implications for human positron 
emission tomography, Synapse 49, 209-215. 
 
57. Usiello, A., Baik, J. H., Rouge-Pont, F., Picetti, R., Dierich, A., LeMeur, M., 
Piazza, P. V., and Borrelli, E. (2000) Distinct functions of the two isoforms of 
dopamine D-2 receptors, Nature 408, 199-203. 
 
58. Fuxe, K., Agnati, L. F., Kalia, M., Goldstein, M., Andersson, K., and Harfstrand, 
A. (1985) Dopaminergic Systems in the Brain and Pituitary, In The Dopaminergic 
System.  Basic and Clinical Aspects of Neuroscience (Fluckiger, E., Ed.), 
Springer-Verlag, Berlin. 
 
59. Giros, B., Jaber, M., Jones, S. R., Wightman, R. M., and Caron, M. G. (1996) 
Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking 
the dopamine transporter, Nature 379, 606-612. 
 
60. Iversen, L. L. (1971) Role of transmitter uptake mechanisms in synaptic 
neurotransmission, British Journal of Pharmacology 41, 571. 
 
 40
61. Jones, S. R., Gainetdinov, R. R., Jaber, M., Giros, B., Wightman, R. M., and 
Caron, M. G. (1998) Profound neuronal plasticity in response to inactivation of 
the dopamine transporter, Proceedings of the National Academy of Sciences of 
the United States of America 95, 4029-4034. 
 
62. Sonders, M. S., Zhu, S. J., Zahniser, N. R., Kavanaugh, M. P., and Amara, S. G. 
(1997) Multiple ionic conductances of the human dopamine transporter: The 
actions of dopamine and psychostimulants, Journal of Neuroscience 17, 960-
974. 
 
63. Smith, Y., and Kieval, J. Z. (2000) Anatomy of the dopamine system in the basal 
ganglia, Trends Neurosci. 23, S28-S33. 
 
64. Nolte, J. (1988) The Human Brain.  An Introduction to its Functional Anatomy, 
Second ed., C.V. Mosby Company, St. Louis. 
 
65. Smeets, W., and Gonzalez, A. (2000) Catecholamine systems in the brain of 
vertebrates: new perspectives through a comparative approach, Brain Research 
Reviews 33, 308-379. 
 
66. Pisani, A., Centonze, D., Bernardi, G., and Calabresi, P. (2005) Striatal synaptic 
plasticity: Implications for motor learning and Parkinson's disease, Movement 
Disorders 20, 395-402. 
 
67. Dingledine, R. (1984) Brain Slices, Plenum Press, New York. 
 
68. Dingledine, R., Dodd, J., and Kelly, J. S. (1980) The invitro brain slice as a useful 
neurophysiological preparation for intracellular-recording, Journal of 
Neuroscience Methods 2, 323-362. 
 
69. Nicholson, C., and Hounsgaard, J. (1983) Diffusion in the slice microenvironment 
and implications for physiological-studies, Federation Proceedings 42, 2865-
2868. 
 
70. Kelly, R. S., and Wightman, R. M. (1987) Detection of dopamine overflow and 
diffusion with voltammetry in slices of rat-brain, Brain Research 423, 79-87. 
 
71. Fleckenstein, A. E., Volz, T. J., Riddle, E. L., Gibb, J. W., and Hanson, G. R. 
(2007) New insights into the mechanism of action of amphetamines, Annu Rev 
Pharmacol Toxicol 47, 681-698. 
 
72. Fischer, J. F., and Cho, A. K. (1979) Chemical-release of dopamine from striatal 
homogenates - evidence for an exchange diffusion-model, Journal of 
Pharmacology and Experimental Therapeutics 208, 203-209. 
 
 41
73. Liang, N. Y., and Rutledge, C. O. (1982) Evidence for carrier-mediated efflux of 
dopamine from corpus striatum, Biochemical Pharmacology 31, 2479-2484. 
 
74. Liang, N. Y., and Rutledge, C. O. (1982) Comparison of the release of H-3 
dopamine from isolated corpus striatum by amphetamine, fenfluramine and 
unlabeled dopamine, Biochemical Pharmacology 31, 983-992. 
 
75. Mack, F., and Bonisch, H. (1979) Dissociation-constants and lipophilicity of 
catecholamines and related-compounds, Naunyn-Schmiedebergs Archives of 
Pharmacology 310, 1-9. 
 
76. Zaczek, R., Culp, S., Goldberg, H., McCann, D. J., and Desouza, E. B. (1991) 
Interactions of H-3 amphetamine with rat-brain synaptosomes .1. saturable 
sequestration, Journal of Pharmacology and Experimental Therapeutics 257, 
820-829. 
 
77. Floor, E., and Meng, L. H. (1996) Amphetamine releases dopamine from 
synaptic vesicles by dual mechanisms, Neuroscience Letters 215, 53-56. 
 
78. Nestler, E. J. (2001) Molecular basis of long-term plasticity underlying addiction, 
Nature Reviews Neuroscience 2, 119-128. 
 
79. Koob, G. F., and Le Moal, M. (2001) Drug addiction, dysregulation of reward, and 
allostasis, Neuropsychopharmacology 24, 97-129. 
 
80. Heikkila, R. E., Orlansky, H., and Cohen, G. (1975) Studies on distinction 
between uptake inhibition and release of H-3 dopamine in rat-brain tissue-slices, 
Biochemical Pharmacology 24, 847-852. 
 
81. Venton, B. J., Seipel, A. T., Phillips, P. E., Wetsel, W. C., Gitler, D., Greengard, 
P., Augustine, G. J., and Wightman, R. M. (2006) Cocaine increases dopamine 
release by mobilization of a synapsin-dependent reserve pool, J Neurosci 26, 
3206-3209. 
 
82. Andersen, P. H. (1989) The dopamine uptake inhibitor GBR 12909 - selectivity 
and molecular mechanism of action, European Journal of Pharmacology 166, 
493-504. 
 
83. Sivam, S. P. (1995) GBR-12909-induced self-injurious-behavior - role of 
dopamine, Brain Research 690, 259-263. 
 
84. Pothos, E. N., Przedborski, S., Davila, V., Schmitz, Y., and Sulzer, D. (1998) D-2-
like dopamine autoreceptor activation reduces quantal size in PC12 cells, Journal 
of Neuroscience 18, 5575-5585. 
 
 42
85. O'Neill, C., Evers-Donnelly, A., Nicholson, D., O'Boyle, K. M., and O'Connor, J. J. 
(2009) D-2 receptor-mediated inhibition of dopamine release in the rat striatum in 
vitro is modulated by CB1 receptors: studies using fast cyclic voltammetry, 
Journal of Neurochemistry 108, 545-551. 
 
86. Moore, K. E., and Dominic, J. A. (1971) Tyrosine hydroxylase inhibitors, 
Federation Proceedings 30, 859-&. 
 
87. Jones, S. R., Garris, P. A., and Wightman, R. M. (1995) Different effects of 
cocaine and nomifensine on dopamine uptake in the caudate-putamen and 
nucleus accumbens, J Pharmacol Exp Ther 274, 396-403. 
 
88. Kawagoe, K. T., Garris, P. A., Wiedemann, D. J., and Wightman, R. M. (1992) 
Regulation of transient dopamine concentration gradients in the 
microenvironment surrounding nerve-terminals in the rat striatum, Neuroscience 
51, 55-64. 
 
89. Mathews, C. K., and van Holde, K. E. (1996) Biochemistry, 2nd ed., 
Benjamin/Cummings, Menlo Park, CA. 
 
90. Garris, P. A., Christensen, J. R. C., Rebec, G. V., and Wightman, R. M. (1997) 
Real-time measurement of electrically evoked extracellular dopamine in the 
striatum of freely moving rats, Journal of Neurochemistry 68, 152-161. 
 
91. Fowler, S. C., Birkestrand, B. R., Chen, R., Moss, S. J., Vorontsova, E., Wang, 
G., and Zarcone, T. J. (2001) A force-plate actometer for quantitating rodent 
behaviors: illustrative data on locomotion, rotation, spatial patterning, 
stereotypies, and tremor, J Neurosci Methods 107, 107-124. 
 
92. Fowler, S. C., Covington, H. E., and Miczek, K. A. (2007) Stereotyped and 
complex motor routines expressed during cocaine self-administration: results 
from a 24-h binge of unlimited cocaine access in rats, Psychopharmacology 192, 
465-478. 
 
 
 
 
 
 43
CHAPTER 2 
 
DOPAMINE RELEASE AND UPTAKE IMPAIRMENTS AND 
BEHAVIORAL ALTERATIONS IN MICE THAT MODEL FRAGILE X 
SYNDROME 
Fulks, J. L., O'Bryhim, B. E., Wenzel, S. K., Fowler, S. C., Vorontsova, E., Pinkston, J. 
W., Ortiz, A. N., and Johnson, M. A. (2010) Dopamine Release and Uptake 
Impairments and Behavioral Alterations Observed in Mice that Model Fragile X 
Mental Retardation Syndrome, ACS Chemical Neuroscience 1, 679-690. 
 
 A clear understanding of the underlying the neurochemical mechanisms of 
neurological disease is vital in the search for therapeutic treatments. This work 
addresses potential alterations in dopamine (DA) release and uptake mechanisms 
associated with fragile X syndrome (FXS), the most common known genetic cause of 
mental retardation.  We have studied the behavioral effects of amphetamine injections 
in Fmr1 knockout (Fmr1 KO) mice, which model FXS, and have evaluated the DA 
release and uptake characteristics in brain slices in order to study the relationship 
between the behavior and neurochemistry.  Behavioral analysis was carried out with the 
use of a force-plate actometer, a device that collects movement information at 
millisecond temporal resolution and 2 mm spatial resolution.  Behavioral analyses  
revealed that, injection with 10 mg/kg (ip) amphetamine,   Fmr1 KO mice expressed a 
lower degree of focused stereotypy  compared to wild type (WT) control mice.  Brain 
slice experiments using fast scan cyclic voltammetry (FSCV) at carbon-fiber 
microelectrodes were performed to identify differences in electrically evoked DA release 
and uptake between KO and WT mice to identify potential mechanisms that would 
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explain the differences seen in the behavioral data.  At 10 weeks of age DA per pulse, a 
measure of dopamine release corrected for electrode performance and reuptake, was 
unchanged between KO and WT mice.  However, at 15 weeks and 20 weeks of age 
there were decreases seen in DA per pulse and in the rate of DA uptake in the KO mice 
compared to the WT mice.  Direct application of amphetamine to the brain slices in 
increasing concentrations showed that there was equal affinity of amphetamine for the 
DA transporter in both the KO and WT mice.  Brain slices were also treated with the 
mGluR5 antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) revealing no immediate 
effect in the recovery of dopamine release in the KO mice.  The D2 autoreceptor 
function was evaluated in slices by application of quinpirole, a D2 agonist, showed that 
there is no change in D2 autoreceptor sensitivity in FXS.  A direct comparison of 
predrug and post drug DA release in the presence of amphetamine showed an 
increased response to amphetamine by the KO mice.  These data support a scenario in 
which inferior extracellular dopamine levels in the striatum explain the diminished 
focused stereotypy in the Fmr1 KO mice.      
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2.1 INTRODUCTION 
 
2.1.1 Fragile X Syndrome 
Fragile X syndrome (FXS), the most common known genetic cause of mental 
retardation and autism occurring in approximately 1 in 1250 males and 1 in 2500 
females (1), is caused by a repeat expansion of greater than 200 CGG repeats on the 
fragile X mental retardation 1 (FMR1) gene located on the X chromosome (2).  The 
repeat expansion leads to a silencing of the transcription of the fragile X mental 
retardation protein (FMRP) (3-4), resulting in neurological impairments.  FMRP plays a 
role in mRNA transport and regulation of their translation (5-8). 
The behavioral manifestation of FXS commonly includes ADHD-like symptoms 
along with communication and motor control disturbances (9-12).  Symptoms that occur 
in FXS are often the same as those that common in cases of autism including repetitive 
behaviors that appear like those of obsessive-compulsive disorder (OCD), anxiety in 
social settings and an increase in sensitivity to sensory stimuli (9-10, 13).  Individuals 
with FXS lack communications skills as is apparent by their lack of eye contact and 
turning their heads and bodies away from others or by attempting to block their eyes 
with their hands and arms (14). 
 
2.1.2 Animal Model of FXS 
In order to investigate FXS and the pathological mechanisms that lead to the 
symptoms of the disorder, an Fmr1 knockout (KO) mouse model was developed in 
which the Fmr1 gene is inactivated (15).  These mice have been used in various studies 
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to evaluate cognition, behavior and therapeutic treatments.  The Fmr1 KO mice have 
been shown to be susceptible to seizure (16-18); however, behavioral measurements 
that utilize spatial learning tasks, such as the Morris water maze, have only been able to 
show mild deficits (19-24).  The maze evaluations could likely show only mild deficits 
because these tasks evaluate learning and memory, but not attention and inhibitory 
control, which are major contributing factor to cognitive deficits in FXS (25).  In more 
recent studies, when presented with attention based tasks, the Fmr1 KO mice exhibited 
a higher rate of premature responses indicating impaired inhibitory control during times 
of stress or arousal (26). 
 
2.1.3 Neurological Manifestations of FXS 
The mutation in FXS may manifest under several different neurological 
mechanisms, influencing brain development.  In recent studies it has been suggested 
that neural development in FXS is impaired as a result of excessive induction of 
hippocampal and cerebellar long-term depression (LTD) (27-28).  The dorsal striatum is 
heavily laden with dopaminergic neurons (29) where the activation of D2 receptors, 
acting in combination with group I mGluRs, CBI cannabinoid receptors and L-type 
calcium channels, is required for the induction of a form of LTD (30-33).  Due to the high 
density of DA in the striatum, an alteration in DA regulation may influence synaptic 
plasticity and brain development (34-35).  Behavioral disorders, such as stereotypy and 
hyperactivity, have been treated by use of DA receptor blockers (36) and are associated 
with FXS (37-38) and autism (39-42).  Thus DA signaling abnormalities are a potential 
neurological disturbance associated with FXS. 
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2.1.4  Dopamine Release Altered by Amphetamine 
The DA system can be challenged by the psychostimulant AMPH to cause an 
excess of extracellular DA (43).  AMPH is often used to evaluate differences in behavior 
between KO mice and their WT counterparts (44-48).  There are dose dependent 
responses to AMPH when evaluating the behavioral response of the animals.  When 
given a low dose (1-2 mg/kg), locomotor stimulation occurs;  at a higher dose (8-10 
mg/kg) an excited state of small repetitive movements of the head, forelimbs and trunk, 
referred to as a focused stereotypy, occur (45, 49).  At very high doses (over 15 mg/kg), 
self-mutilation is sometimes seen (50-51).  Previous studies performed with AMPH 
doses on Fmr1 KO mice were done with doses well below the focused stereotypy range 
(47-48).   
The doses of AMPH used in this work were within the ranges for increased 
locomotor activity and focused stereotypy, but below the threshold for self-mutilation.   
There is a wide acceptance that the focused stereotypy behavior caused by AMPH is in 
part due to increased levels of DA in the dorsal striatum (52-53).  The behavioral 
changes caused by the AMPH injections were measured using a force-plate actometer, 
described in Chapter 1 of this work, which is capable of distinguishing between 
locomotor activity and focused stereotypy.    
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2.2 EXPERIMENTAL PROCEDURES 
 
2.2.1 Animals 
All animal procedures were conducted in accordance with protocols approved by 
the Animal Care and Use Committee of the University of Kansas.  Fragile X knockout 
mice FVB.129P2-Fmr1tm1Cgr/J (19) and wild-type control mice were obtained from The 
Jackson Laboratory (Bar Harbor, ME, USA).  These mice were received at 
approximately 8 weeks of age and were housed in the University of Kansas Animal 
Care Unit (ACU) under a temperature-regulated, humidity-controlled environment.  The 
mice had unrestricted access to food and water and were housed with 12 hour light/dark 
cycles.   
 
2.2.2 Drugs 
d-Amphetamine sulfate, GBR12909, quinpirole, and cocaine were purchased 
from Sigma-Aldrich (St. Louis, MO).   
 
2.2.3 Behavior 
Behavioral Apparatus.  Behavioral data were collected during the light phase of the 
housing light/dark cycle.  Eight force-plate actometers (54) were utilized in the collection 
of behavioral data for the comparison of behavioral characteristics between KO and WT 
mice.  Each actometer measured 28 cm X 28 cm and in order to prevent alterations in 
behavior due to outside noises, the actometers were placed in sound-attenuating 
chambers.  In order to provide ventilation, a silent, vibration free ventilation system was 
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utilized. Animal activity was tracked by force measurements being recorded at a rate of 
100 pts/s with a spatial resolution less than 2 mm.  Vertical forces both associated with 
locomotion and non-locomotor movements were also recorded and analyzed.  
Locomotor activity in rodents is commonly reported in the form of distance traveled, 
which was determined by summing the distances between consecutive center of force 
coordinate 0.5 s apart.  By utilizing this measuring system the locomotion is 
accentuated and the contribution to the distance variable of small, high-frequency 
movements is reduced. The force-plate method has been used to measure the mouse 
behavior even while the animal is “staying in place” allowing the quantitation on focused 
stereotypy (49) induced by central nervous system stimulants, such as amphetamine 
(55) or cocaine (56).  A combination of the animal remaining in one location (spatial 
confinement) in combination with the vigor of head, limb and trunk activity (while 
confined) was used to determine the FS score.  In order to determine the FS score, the 
floor area of the actometer was divided into 256 equal-sized square sectors. One 
minute intervals were used to calculate the percent of time the animal spent in each 
sector.  Computation of the FS score was then done by the following:  1) multiplying the 
variance in the vertical force in a sector by the percent time in the same sector; 2) the 
products across all of the 256 sectors were summed; and 3) this sum of the products 
was then divided by the number of sectors used during the 1-min time period to obtain 
the FS score.  The average of 60 1-min FS scores was taken to obtain the FS score for 
a 60-min time period. 
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Behavioral Procedures.  Fifteen-week old Fmr1 KO mice and age-matched WT control 
mice were placed in the actometers for two 1-hr recording sessions conducted 10 days 
apart.  A few seconds before sessions, separate groups of n = 6 mice each received ip 
injections of saline vehicle, 1.0, 3.3, or 10.0 mg/kg of d-amphetamine sulfate. In 
experimental design terminology this was an analysis of variance (ANOVA) with 2 
genotypes, 4 doses, and 2 injections as a repeated measures variable. Therefore, the 
procedure dictated the use of 24 WT and 24 KO mice.  Doses of amphetamine were 
selected to produce locomotor stimulation at the two lower doses and focused 
stereotypy at the highest dose in WT mice. 
 
2.2.4 Brain slice preparation 
Striatal brain slices were prepared as described previously (57).  Briefly, mice 
were anesthetized by inhalation of isoflurane gas and decapitated.  The brain was 
removed immediately and placed into ice-cold artificial cerebrospinal fluid (aCSF) 
saturated with 95%O2/5%CO2   The aCSF solution consists of (in mM) 126 NaCl, 22 
HEPES, 1.6 NaH2PO4, 2.5 KCl, 25NaHCO3, 2.4 CaCl2, 1.2 MgCl2, and 11 D-glucose, and 
was adjusted to a pH of 7.4.  For support while slicing, a 1 cm3 block of agar gel was 
glued to the support block.  The cerebellum was removed with a razor blade and the 
brain was bisected.  Next, the brain was glued to the support block with Roti®coll 1 (Carl 
Roth, Karlsruhe, Germany), a quick-setting glue, and the buffer tray was then filled with 
ice-cold aCSF.  The remaining half of the brain was dissected and the striatum removed 
and placed on dry ice and stored at -80°C for HPLC analysis.  Coronal slices 300µm 
thick were made using a Leica VT1000 S vibrating-blade microtome (Leica 
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Microsystems, Nussloch, Germany).  Striatal slices obtained between 0.4mm and 
1.60mm anterior to bregma were used for voltammetry analyses.  The brain slices were 
stored in ice-cold aCSF saturated with 95%O2/5%CO2 until needed for use.  Prior to 
experimentation, slices were placed in a perfusion chamber with aCSF continuously 
flowing (1 mL/min) and kept at a temperature of 34°C.  Slices were allowed to 
equilibrate in the perfusion chamber for at least 90 minutes before data collection.  
Drugs were introduced to slices through a three-way valve that allowed aCSF 
containing the chosen drug to flow from a separate reservoir to the slice chamber.   
 
2.2.5 Fast-Scan Cyclic Voltammetry 
 Microelectrodes, with the exposed carbon-fiber tip having a diameter of 7 µm 
and a length of 30 µm, were constructed as previously described (58).  Electrodes were 
calibrated before and after use by exposure to known DA concentrations in a flow cell.  
The stimulation electrodes were made by gluing two tungsten electrodes (A-M Systems 
Inc, Carlsborg, WA, USA) and adjusting the distance between the two tips using heat 
shrink (3M Electronics, Austin, TX, USA) until they were 200 µm apart.  Electrochemical 
measurements were obtained using an Axopatch 200B amplifier (Molecular Devices, 
Sunnyvale, CA) interfaced with a computer through a locally constructed breakout box 
and custom designed software written by M.L.A.V. Heien and R. M. Wightman, 
Department of Chemistry, University of North Carolina, Chapel Hill, NC.     
For brain slice experiments, carbon fiber microelectrodes were inserted 100 µm 
below the surface of the brain slice between the two stimulus electrodes, situated in the 
dorsolateral caudate.  To obtain most measurements, DA release was evoked by the 
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application of a single, biphasic, electrical pulse (4 ms duration, 350 µA current).  A 
series of 50 stimulus pulses applied at 10 Hz was used when evaluating the effects of 
quinpirole and cocaine.  To detect released DA, a triangular waveform was applied to 
the carbon fiber microelectrode in which the potential was linearly scanned from a 
holding potential of -0.4 V to +1.0 V and back to -0.4 V at a scan rate of 300 V/sec and 
an update rate of 10 Hz.  A Ag/AgCl reference electrode was used.  Currents measured 
prior to stimulation were subtracted from those measured during and immediately after 
stimulation to yield a cyclic voltammogram for DA.  To measure DA release in the 
absence of drugs, recordings were collected from four different locations within the 
dorsolateral caudate region of each slice and averaged (57).  This averaging approach 
decreased variability caused by the heterogeneous nature of dopaminergic innervation 
in the striatum.   
Stimulated release plots were modeled using software written by R. M. 
Wightman, University of North Carolina, Chapel Hill, NC.  From this modeling operation, 
kinetic parameters associated with dopamine release and uptake were calculated.  
These parameters include dopamine per pulse [DA]p, which is peak dopamine release 
corrected for electrode performance and reuptake, KM, and Vmax.  The approach used 
here is similar to that applied previously to FSCV data obtained using brain slices (57).     
 
2.2.6 High Performance Liquid Chromatography 
High Performance Liquid Chromatography (HPLC) analyses of catecholamine 
content were carried out using a Shimadzu Model LC 20 AD, (Shimadzu Corporation, 
Kyoto, Japan) with a dual reciprocating pump and a DGV 20A3 degasser and a model 
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CBM 20A system controller.  An ESA Coulochem II electrochemical detector (ESA, Inc., 
Chelmsford, MA, USA), consisting of a guard cell and two analytical cells, was used for 
detection of catecholamines in striatal lysates.  The guard cell was set at 350 mV.  The 
analytical cells were set at -150mV for the first detector and +220 mV for the second 
detector.  Mobile phase consisted of 10% organic phase (acetonitrile) and 90% aqueous 
phase (containing 75 mM sodium dihydrogen phosphate monohydrate, 0.01% 
trietheylamine, 25µM EDTA tetrasodium tetrahydrate, and 1.7mM 1-Octanesulfonic acid 
sodium salt) adjusted to a pH of 2.8 with 80% phosphoric acid.  Chromatographic 
separations were carried out isocratically using a 150mm × 3.2 mm ESA MD-150 
column.  The flow rate was set to 0.4 mL/min. 
Animals were euthanized and the striata removed and stored at -80°C until 
analysis.  For analysis, tissue was prepared by homogenizing in 0.500 ml of 0.2N 
perchloric acid containing 200ng/ml DHBA as internal standard.  Homogenate was 
centrifuged at 14,000 rpm for 20 minutes at 4°C.  Supernatant was removed and filtered 
through a 0.2 micron syringe filter prior to injection in the HPLC instrument.  Standard 
curve solutions were prepared immediately prior to each HPLC run by dissolving pure 
substance in 0.2 N perchloric acid containing 200ng/ml internal standard and diluting by 
serial dilution.  Nine concentrations were used for each compound (1000, 500, 200, 
100, 50, 25, 10, 5 and 1 ng/ml).   
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2.2.7 Genotype verification 
 Tail snips were saved from each mouse to use in genotyping to verify each 
animals genotype. A DNeasy Blood and Tissue kit (QIAGEN, Valencia, CA, USA) was 
used for DNA extraction.  Primer sequences were made according to the design on the 
Jackson Laboratory website and were purchased from Invitrogen (Carlsbad, CA, USA).  
A 5 mM cresol Red diluted in a 60% sucrose solution was used as the loading dye.  
After DNA extraction and PCR, samples were loaded onto a 1.5% agarose gel with 5 µL 
of ethidium bromide and were run in a TAE buffer.  Each mouse DNA sample was 
separated into two different PCR reactions; A and B.  Where a band detected in lane A 
indicated WT and a band in lane B indicated KO.   All genotypes were proved to be 
correctly labeled.   
 
2.2.8 Statistical Analyses  
Statistical analyses were performed using either student’s t-test or ANOVA.  A 
value of p < 0.05 was considered significant.  Values are expressed as average ± SEM. 
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2.3 RESULTS AND DISCUSSION 
 
2.3.1 Behavioral Results 
2.3.1.1  Locomotor activity 
 Locomotor activity, expressed as distance traveled shown in Figure 2 (panels A 
& B), was significantly higher in the Fmr1 KO mice in the absence of AMPH after both 
vehicle injections.  Our results are consistent with previous studies reporting on 
locomotor activity in Fmr1 KO mice (48-49, 59-65).  Methods utilized in these prior 
studies included multiple brands of photobeam actometers, manual counting of line 
crossings, and computer scored video tracking.  Some studies report a non significant 
difference between the KO and WT mice (62-64); however, the data reported indicated 
that the Fmr1 KO mice were numerically higher than the WT mice.  It appears that the 
lesser differences in locomotor activity are associated with shorter recording times.     
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Figure 2.  Induction of locomotor activity and focused stereotypy by d-amphetamine sulfate in 
Fmr1 knockout and WT control mice.  Separate groups of mice (n=6) were used at each dose.  Data 
points are group means and the brackets indicate ± SEM.  The four symbols, asterisks (*), ampersands 
(&),  pound signs (#), and dollar sign($)  reflect significant differences between means as determined by t-
tests conducted after initial 3-way ANOVA’s.  *’s indicate significant differences between Wild type (WT) 
and Fmr1 knockout mice at the indicated doses.  &’s designate significant differences between vehicle 
and each dose of amphetamine for WT mice for a given injection, while #’s mark differences between 
vehicle and each amphetamine dose administered to the Fmr1 mice.  $’s, used in Panel D only, 
designate differences between injection 1 and injection 2 for a given genotype. (A) Distance traveled-
Injection 1: * WT vs Fmr1KO at dose 0: t10=4.16, p<0.01. &: WT:  0 vs 1.0 mg/kg, t10=4.42, p<0.01; 0 vs 
3.3 mg/kg, t10=4.50, p<0.01; and 0 vs 10.0 mg/kg, t10=2.34, p<0.05 (a decrease). # Fmr1: 0 vs 1.0 mg/kg, 
t10=3.24, p<0.01; 0 vs 3.3 mg/kg, t10=2.53, p<0.05; and 0 vs 10.0 mg/kg, t10=5.50, p<0.01.  (B) Distance-
Injection 2:  * WT vs Fmr1 KO at dose 0: t10=2.98, p<0.01; WT vs Fmr1 at dose 3.3 mg/kg, t10=6.29, 
p<0.001. &: WT: 0 vs 1.0 mg/kg, t10=4.12, p<0.01; 0 vs 3.3 mg/kg, t10=7.69, p<0.01. # Fmr1: 0 vs 1.0 
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mg/kg, t10=4.25, p<0.01; 0 vs 3.3, t10=3.32, p<0.01; 0 vs 10.0 mg/kg, t10=4.25, p<0.01 (a decrease).  (C) 
Focused Stereotypy-Injection 1: * WT vs Fmr1 at dose 10.0 mg/kg, t10=2.897, p<0.05. (D) Focused 
Stereotypy-Injection 2:  * WT vs Fmr1 at dose 10.0 mg/kg, t10=3.33, p<0.01; $ Injection 2 vs injection 1: 
Wt: t10=2.60, p<0.05; Fmr1: t10=3.04, p<0.05 (66).  Figure taken from Fulks et al. 2010. 
 
AMPH stimulated locomotor activity at the two lower doses but decreased 
locomotor activity at the 10 mg/kg dose.  Each dose group for injection 1, regardless of 
genotype, showed a significant dose response to AMPH, either by an increase in 
locomotion at the lower doses, or with a decrease in the high dose.    The dose effect 
pattern for injection 2 was similar to the pattern in Injection 1 with two exceptions.  In the 
3.3 mg/kg AMPH dose the Fmr1 KO mice were significantly lower than the WT mice, 
and at the 10 mg/kg dose the WT mice were not significantly lower than the WT mice 
under vehicle conditions, likely due to the low distance traveled by the WT mice 
receiving the vehicle after the second injection.  Previous studies have reported that at 
2.0 mg/kg AMPH there was no significant increase in locomotor activity (48-49), 
however, this discrepancy may due to the enhanced temporal and spatial resolution of 
the force-plate method.   
 
2.3.1.2 Focused Stereotypy 
 Focused stereotypy data for AMPH dose-effect are shown in Figure 2 (Panels C 
and D).  The 3-way ANOVA of focused stereotypy measurements indicated significant 
main effects of mouse type, dose and injection number.  A significant dose interaction 
was seen with both injection number and mouse type.  A 2-way post hoc, type x 
injection # ANOVA at the 10.0 mg/kg dose showed significantly greater focused 
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stereotypy in the WT mice than in the Fmr1 KO mice on both injection days.  Focused 
stereotypy for both KO and WT mice was significantly higher after injection 2 compared 
to injection 1.  These data suggest that the Fmr1 KO mice have a diminished high-dose 
response to AMPH.  For the focused stereotypy measure, AMPH dose effects were not 
detected when the 10.0 mg/kg dose groups were removed from the analysis, showing 
that the WT-KO differences in focused stereotypy was primarily at the 10.0 mg/kg dose.   
 
2.3.2 DA Release in the Dorsal Striatum 
 Previous evidence suggests that focused stereotypy expression is strongly 
influenced by increased extracellular DA levels in the dorsal striatum (53).  Therefore, 
the differences in AMPH-induced stereotypic behavior between KO and WT mice 
prompted us to determine DA release and uptake characteristics in striatal brain slices 
from Fmr1 KO and WT mice.  FSCV was used to generate plots of stimulated DA 
release and uptake Figure 3.   
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Figure 3.  DA release is impaired in 15 week-old Fmr1 KO mice.  Representative plots of electrically 
stimulated DA release obtained in brain slices from a 15 week-old Fmr1 KO mouse and an age-matched 
WT control mouse.  The application of a single, biphasic electrical stimulus pulse (4 ms total duration, 350 
µA current) is denoted by the arrow under each plot.  Cyclic voltammograms, provided above each plot, 
confirm the presence of DA.  
 
Curve modeling software was then used to calculate DA released per stimulus 
pulse ([DA]p), which is peak DA release corrected for uptake and electrode 
performance, and Vmax, the maximum rate of DA uptake (Figure 4).  Values obtained 
from Fmr1 KO mice were normalized against corresponding WT values.  At 10 weeks of 
age, no significant differences in [DA]p was noted between KO mice (n=7) and WT mice 
(n=7).  This finding is consistent with voltammetric measurements obtained previously in 
Fmr1 KO mice (67).  However, at 15 (KO n=6 and WT n=6) and 20 (KO n=10 and WT 
n=10) weeks of age, [DA]p was diminished in KO mice compared to WT mice (p< 0.05 
and p<0.001 respectively).  Similarly, Vmax was the same in the KO and WT mice at 10 
 60
weeks of age, but was decreased in KO mice at 15 and 20 weeks of age.  It is not 
known why impairments in release and uptake develop later in life in KO mice; however, 
this finding may imply that neurochemical changes occur into adulthood in humans with 
fragile X syndrome.   
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Figure 4.  [DA]p and Vmax are impaired in 15- and 20-week old KO mice compared to aged-matched 
WT control mice.  (A) The open circles represent the experimental data, while the line shows the model 
fit to the data.  (B) When the stimulated DA release of the KO mice were compared to the WT mice, a 
significant difference in the release was seen at 15 and 20 weeks of age.  (C) By modeling the data, Vmax 
was also determined and the KO compared to the WT.  A significant decrease in Vmax was seen in the 15 
and 20 week old mice.  
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 A potential underlying cause for the decrease in [DA]p noted in the older KO mice 
is a diminishment in the amount of DA available for release.  Therefore, striatal 
catecholamine content was measured using high performance liquid chromatography 
(HPLC) with electrochemical detection (68).  Total DA content was the same between 
age groups and genotype (n=4 to 7 mince; Table 1).  Moreover, no differences were 
noted in the striatal content of 3,4-dihydroxyphenylacetic acid (DOPAC) and 
homovanillic acid (HVA), two metabolites of DA.  Therefore, even though sufficient DA 
stores are present in the KO striatum, these stores are not released as effectively as in 
the WT mice.   
 
Table 1.  Catacholamine content in striatal lysates from KO and WT mice.  No significant differences 
in the content of DA, DOPAC, or HVA were noted between KO and WT.  The n-values in parentheses 
indicate number of mice.  
   KO    WT  
Age 
(weeks) 
 
 DA(ng/g) DOPAC(ng/g) HVA(ng/g)  DA(ng/g) DOPAC(ng/g) HVA(ng/g) 
10  10166 ± 
623 (n=5) 
1077 ± 91 
(n=5) 
1336 ± 79 
(n=5) 
 9529±329 
(n=7) 
1154 ± 91 
(n=7) 
1536 ± 81 
(n=7) 
15  9934±1051 
(n=5) 
764 ± 81  
(n=5) 
1177 ± 
113 (n=5) 
 8796±637 
(n=6) 
805 ± 38  
(n=6) 
1483 ± 186 
(n=6) 
20  9375±624 
(n=5) 
1294 ±382 
(n=5) 
2546 ± 
596 (n=5) 
 9653±967 
(n=4) 
1419 ± 250 
(n=4) 
1481 ± 111 
(n=4) 
 
 
2.3.3 D2 Autoreceptor Function 
 Presynaptic D2 autoreceptors are G-protein coupled receptors that inhibit DA 
synthesis and release upon activation (69).  To determine if D2 autoreceptor over-
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activation causes decreased [DA]p in KO mice, striatal brain slices from 20-week old 
mice were treated with increasing concentrations of quinpirole, a D2 agonist (70).  After 
treatment with the maximum quinpirole concentration of 150 nM, DA release 
disappeared (Figure 5).  No significant interactions between drug concentration and 
genotype were found (ANOVA, p>0.05, KO n=4 and WT n=6); therefore, over-activation 
of D2 autoreceptors is not a likely underlying cause of decreased release in KO mice.   
 
Figure 5.  D2 autoreceptor activation similarly and cocaine induced reserve pool activation were 
similar in WT and KO mice.  (A) Representative data collected in a striatal brain slice from a 20 week 
old WT mouse.  The slice was exposed to cumulatively increasing concentrations of quinpirole while 
measuring electrically-evoked DA release every 5 minutes.  After DA release disappeared, cocaine was 
added to the slice with the quinpirole to mobilize reserve pool DA.  (B) Quinpirole inhibited DA release 
similarly in WT and KO mice (ANOVA).  (C) The percent DA recovery post quinpirole and cocaine showed 
no difference in the KO and WT mice.   
 
 
 63
 An important aspect of D2 autoreceptor function is inhibition of DA synthesis.  
Continuous treatment with quinpirole and concurrent application of periodic electrical 
stimulus pulses should deplete terminals of releasable DA, leaving only reserve pool 
DA.  To identify potential differences in reserve pool mobilization and content, cocaine 
(10 µM) was added to the slices in addition to the quinpirole (150 nM) already present, 
and the stimulation regiment of a series of 50 pulses applied at 10 Hz every 5 minutes 
was continued.  The purpose of using the extended pulse sequences opposed to single 
pulses was to facilitate the depletion of releasable DA.  Cocaine has been shown to 
mobilize a synapsin dependent DA reserve pool (71-72).  Therefore, as expected, within 
5 minutes, the reserve pool vesicles were mobilized and the stimulated release peak 
reappeared.  After 30 minutes of cocaine exposure, KO and WT stimulated release 
peaks, expressed as a percentage of the pre-drug peak, were compared (Figure 5C).  
These values did not differ significantly (student’s t-test, KO n=4 and WT n=6, p > 0.05), 
indicating that similar amounts of reserve pool DA were mobilized in KO and WT mice.   
 
2.3.4 Neurochemical Response to AMPH 
 To compare the DA uptake efficiencies between KO and WT mice, brain slices 
from both genotypes were treated with successively increasing concentrations of 
AMPH, which inhibits DA uptake through the DA transporter (DAT).  Drug response 
curves were then obtained by plotting the average KM values against [AMPH].  Linear 
regression analyses reveal that the slopes for the KO and WT curves both deviate 
significantly from zero (p < 0.001, n=4 KO and 4 WT mice) and analyses by 2-way 
ANOVA show that there is no significant interaction between genotype and AMPH 
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concentration (Figure 6).  Therefore, differences in behavioral activation due to AMPH 
administration likely do not arise from differences in the affinity of AMPH for DAT.   
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Figure 6.  DA uptake is similarly inhibited in the KO and WT striatum.  The stimulated release plots 
(open circles) were modeled (solid line) to determine KM for DA uptake during a cumulative treatment 
regimen.  Average values of KM at each AMPH concentration were determined and plotted (inset).  There 
was no significant interaction between genotype and KM or between genotype and [AMPH] (ANOVA).   
 
 Further analyses of these data revealed no differences in [DA]p between KO and 
WT mice at any given concentration of AMPH (Figure 7); however, a concern with 
these release values was that genotype-related differences in [DA]p could be masked by 
the high degree of heterogeneity of dopaminergic innervations within the striatum.  To 
account for this variability, we used a separate experimental approach in which DA 
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release was sampled from four locations in the dorsolateral caudate and averaged, both 
before and after treating the slice with 6 µM AMPH (a concentration that provided a 
large increase in KM but did not appear to cause diminished release).  However, DA 
release plots obtained in this way were not amenable to modeling because Vmax 
changes when the working electrode is moved to different locations within the striatum.  
Because curves generated from these measurements were not modeled, the DA 
release values were uncorrected for uptake.  For each slice, the peak DA release 
values after AMPH treatment were expressed as a percentage of average release prior 
to treatment (% no drug release).  Slices were averaged to obtain a value for each 
mouse.  These data revealed that % no drug release was significantly greater in the KO 
mice than in the WT mice (p < 0.01, t-test, n=4 WT and 4 KO mice; Figure 7) and 
indicate that AMPH treatment enhanced DA release in slices from KO mice, but not in 
slices from WT mice.  The raw values of DA release following AMPH treatment were 
1.50 ± 0.31 µM in KO mice and 0.58 ± 0.46 µM in WT mice (p < 0.05, t-test, n=4 WT 
and 4 KO mice).   
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Figure 7.  AMPH enhances stimulated DA release in brain slices from KO mice, but not in those 
from WT mice.  Representative plots of stimulated DA release are shown for WT and KO mice before 
(solid lines) and after (dashed lines) treatment with 6 µM AMPH.  After AMPH administration, stimulated 
DA release increased, relative to pre-drug values in KO mice, but not in WT mice (inset).  Statistics: *p < 
0.01, t-test, n = 4 WT and 4 KO mice.   
 
 AMPH empties DA from presynaptic terminals and vesicles.  To do this, it first 
enters terminals either through membrane-bound DAT protein molecules or by lipophilic 
diffusion through the membrane.  AMPH that enters through the DAT causes allosteric 
translocation of the protein and induces the reverse transport of DA from the cytosol to 
the extracellular space (73-75).  Additionally, AMPH displaces vesicular DA into the 
cytoplasm where it can then be released by reverse transport (73, 76).  Thus, the 
availability of DAT protein molecules for both AMPH entrance and for DA reverse 
transport should impact extracellular DA levels in AMPH-injected mice.   
 Our data show a decrease in Vmax in KO mice at 15 and 20 weeks of age.  
According to Michaelis-Menton kinetics, Vmax is directly proportional to the number of 
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functioning DAT protein molecules (77) (Vmax – kcat[E]t where kcat is a rate constant and 
[E]t is the total enzyme concentration).  This means that less transporter protein 
molecules function properly in KO mice compared to WT mice.  Logically, our 
voltammetric data are consistent with a scenario in which AMPH cannot enter, and DA 
cannot leave, terminals in the Fmr1 KO striatum as readily as in the WT striatum.  
Therefore, DA is able to reside within the terminals and vesicles for a longer period of 
time in the KO striatum and is, therefore, available for release in the event of an action 
potential.  These neurochemical results are consistent with those of Ventura et al. (47), 
who found that AMPH induces a smaller increase in extracellular striatal DA levels in 
KO mice compared to WT mice.  More importantly, however, these neurochemical 
results agree with our behavioral data in the case of 15 week old KO mice which 
showed diminished expression of focused stereotypy compared to age matched WT 
mice.   
 
2.3.5 DA response to GBR12909 
 The effect of slice exposure to GBR12909 (GBR) was also evaluated.  Unlike 
AMPH, GBR is a selective DAT blocker thus inhibiting DA uptake and has been shown 
to cause an increase in extracellular DA levels (78-80).  GBR was administered to slices 
by perfusion in increasing concentrations (25, 50 and 100µM) over time, while collecting 
stimulated DA release data.  The data were modeled to determine KM values for each 
concentration (Figure 8).  A plot of KM vs. concentration of GBRsuggests that the 
affinity of GBR for DAT is the same in both the WT and KO mice (Figure 8).   
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Figure 8.  GBR-12909 brain slice data.  The data was modeled using modeling software and values of KM 
were plotted against the concentration of GBR-12909 showing no alterations in the affinity of GBR-12909 
for DAT in the KO mice. 
 
2.3.7 DA release and the mGluR Theory 
 Metabotropic glutamate receptors (mGluR)  and FMRP are important in the 
regulation of mRNA transcription (8, 81).  Evidence indicates a hypersensitivity of 
mGluR’s in FXS which contributes to the phenotype (5, 82-83).  The use of an mGluR 
antagonist 2-methyl-6-(phenylethynyl)pyridine (MPEP) has been shown to recover 
some of the phenotypic behavior associated with FXS when given to Fmr1 mutant 
Drosophila over time (84).  We have shown that FXS has diminished stimulated release 
in the 15 and 20 week old age groups likely connected to the behavioral differences 
seen between the KO and WT mice.  To evaluate the effect of antagonizing the 
mGluR’s on DA release, we exposed slices to MPEP to determine if it would recover 
stimulated DA release in the KO mice.  Slices from 10 week and 20 week old mice were 
exposed to 46 µM & 30 µM MPEP respectively.  Stimulated release data was collected 
from four locations in each slice before and after MPEP exposure.  The data were 
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reported as a % of the predrug release (Figure 9).  We were unable to detect any 
immediate effect on stimulated DA release when exposing the slices to MPEP (p > 0.05, 
n=6 for 10 week old and n=3 for 20 week old).   
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Figure 9.  Stiumulated DA response to MPEP exposure on slices.  No significant difference was seen in 
either the 10 week or 20 week old groups.  (p>0.05, n=6 for 10 week old mice and n=3 for 20 week old 
mice) 
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2.4 CONCLUDING REMARKS 
 
 To our knowledge, this is the first published study to use the force-plate 
actometer to provide quantitative measurements of behavior in Fmr1 KO mice in 
comparison to WT control mice.  This method has the utility of being able to identify and 
quantify rodent behavior even when the animal is not locomoting.  Our results reveal a 
significant difference in behavioral response to AMPH injection.  In particular, Fmr1 KO 
mice are resistant to the expression of AMPH-induced focused stereotypy.  Our DA 
release plots support the concept that this resistance is potentially influenced not only 
by an impairment in the ability of these mice to release DA, but also by decreased 
AMPH-induced efflux of DA from terminals in the Fmr1 KO striatum.  Moreover, 
because these neurochemical differences were found only in mice 15 weeks of age or 
older, it may be that changes in DA release and uptake occur into adulthood of 
individuals with fragile X syndrome. 
 
ACKNOWLEDGMENT  
This project was funded by:  the National Institutes of Health (NIH) from the IDeA 
Network of Biomedical Research Excellence (INBRE) Program of the National Center 
for Research Resources under the award P20 RR016475 (MAJ); the Kansas City Area 
Life Sciences Institute and TEVA Neuroscience, Inc. (MAJ); and by the Life Span 
Institute (P30-HD02528) at the University of  Kansas (SCF).   
 
 
 
 
 71
2.5 REFERENCES 
 
 
1. Webb, T. P., Bundey, S., Thake, A., and Todd, J. (1986) The frequency of the 
fragile X chromosome among schoolchildren in Coventry, J Med Genet 23, 396-
399. 
 
2. Verkerk, A. J., Pieretti, M., Sutcliffe, J. S., Fu, Y. H., Kuhl, D. P., Pizzuti, A., 
Reiner, O., Richards, S., Victoria, M. F., Zhang, F. P., and et al. (1991) 
Identification of a gene (FMR-1) containing a CGG repeat coincident with a 
breakpoint cluster region exhibiting length variation in fragile X syndrome, Cell 
65, 905-914. 
 
3. Feng, Y., Zhang, F. P., Lokey, L. K., Chastain, J. L., Lakkis, L., Eberhart, D., and 
Warren, S. T. (1995) Translational suppression by trinucleotide repeat expansion 
at FMR1, Science 268, 731-734. 
 
4. Oberle, I., Rousseau, F., Heitz, D., Kretz, C., Devys, D., Hanauer, A., Boue, J., 
Bertheas, M. F., and Mandel, J. L. (1991) Instability of a 550 base pair DNA 
segment and abnormal methylation in FRAGILE X-syndrome, Science 252, 
1097-1102. 
 
5. Bear, M. F., Huber, K. M., and Warren, S. T. (2004) The mGluR theory of fragile 
X mental retardation, Trends Neurosci 27, 370-377. 
 
6. Huot, M. E., Bisson, N., Davidovic, L., Mazroui, R., Labelle, Y., Moss, T., and 
Khandjian, E. W. (2005) The RNA-binding protein fragile X-related 1 regulates 
somite formation in Xenopus laevis, Molecular Biology of the Cell 16, 4350-4361. 
 
7. Siomi, H., and Dreyfuss, G. (1997) RNA-binding proteins as regulators of gene 
expression, Curr. Opin. Genet. Dev. 7, 345-353. 
 
8. Siomi, H., Siomi, M. C., Nussbaum, R. L., and Dreyfuss, G. (1993) The protein 
product of the fragile X gene, FMR1, has characteristics of an RNA-binding 
protein, Cell 74, 291-298. 
 
9. Cornish, K., Sudhalter, V., and Turk, J. (2004) Attention and language in fragile 
X, Mental Retardation and Developmental Disabilities Research Reviews 10, 11-
16. 
 
10. Hagerman, R. J., and Hagerman, P. J. (2002) The fragile X premutation: into the 
phenotypic fold, Curr Opin Genet Dev 12, 278-283. 
 
11. Hatton, D. D., Hooper, S. R., Bailey, D. B., Skinner, M. L., Sullivan, K. M., and 
Wheeler, A. (2002) Problem behavior in boys with fragile X syndrome, Am. J. 
Med. Genet. 108, 105-116. 
 72
 
12. Maes, B., Fryns, J. P., Vanwalleghem, M., and Vandenberghe, H. (1994) 
Cognitive-functioning and information-processing of adult mentally-retarded men 
with fragile-X syndrome, Am. J. Med. Genet. 50, 190-200. 
 
13. Reiss, A. L., and Freund, L. (1992) Behavioral-phenotype of fragile-X syndrome - 
DSM-III-R autistic behavior in male-children, Am. J. Med. Genet. 43, 35-46. 
 
14. Hagerman, R. J. (1996) Fragile X syndrome, Child Adolesc. Psychiatr. N. Am. 5, 
895-&. 
 
15. (1994) The Dutch-Belgian Fragile X Consortium.  Fmr1 knockout mice: a model 
to study fragile X mental retardation. , Cell 78, 23-33. 
 
16. Musumeci, S. A., Ferri, R., Scuderi, C., Bosco, P., and Elia, M. (2001) Seizures 
and epileptiform EEG abnormalities in FRAXE syndrome, Clinical 
Neurophysiology 112, 1954-1955. 
 
17. Musumeci, S. A., Hagerman, R. J., Ferri, R., Bosco, P., Dalla Bernardina, B., 
Tassinari, C. A., De Sarro, G. B., and Elia, M. (1999) Epilepsy and EEG findings 
in males with fragile X syndrome, Epilepsia 40, 1092-1099. 
 
18. Yan, Q. J., Rammal, M., Tranfaglia, M., and Bauchwitz, R. P. (2005) Suppression 
of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 
antagonist MPEP, Neuropharmacology 49, 1053-1066. 
 
19. Bakker, C. E., Verheij, C., Willemsen, R., Vanderhelm, R., Oerlemans, F., 
Vermey, M., Bygrave, A., Hoogeveen, A. T., Oostra, B. A., Reyniers, E., 
Deboulle, K., Dhooge, R., Cras, P., Vanvelzen, D., Nagels, G., Martin, J. J., 
Dedeyn, P. P., Darby, J. K., and Willems, P. J. (1994) Fmr1 Knockout Mice - a 
Model to Study Fragile-X Mental-Retardation, Cell 78, 23-33. 
 
20. Dhooge, R., Nagels, G., Franck, F., Bakker, C. E., Reyniers, E., Storm, K., Kooy, 
R. F., Oostra, B. A., Willems, P. J., and DeDeyn, P. P. (1997) Mildly impaired 
water maze performance in male Fmr1 knockout mice, Neuroscience 76, 367-
376. 
 
21. Dobkin, C., Rabe, A., Dumas, R., El Idrissi, A., Haubenstock, H., and Brown, W. 
T. (2000) Fmr1 knockout mouse has a distinctive strain-specific learning 
impairment, Neuroscience 100, 423-429. 
 
22. Kooy, R. F., Dhooge, R., Reyniers, E., Bakker, C. E., Nagels, G., DeBoulle, K., 
Storm, K., Clincke, G., DeDeyn, P. P., Oostra, B. A., and Willems, P. J. (1996) 
Transgenic mouse model for the fragile X syndrome, Am. J. Med. Genet. 64, 
241-245. 
 
 73
23. Paradee, W., Melikian, H. E., Rasmussen, D. L., Kenneson, A., Conn, P. J., and 
Warren, S. T. (1999) Fragile X mouse: Strain effects of knockout phenotype and 
evidence suggesting deficient amygdala function, Neuroscience 94, 185-192. 
 
24. Peier, A. M., McIlwain, K. L., Kenneson, A., Warren, S. T., Paylor, R., and 
Nelson, D. L. (2000) (Over)correction of FMR1 deficiency with YAC transgenics: 
behavioral and physical features, Human Molecular Genetics 9, 1145-1159. 
 
25. McNaughton, C. H., Moon, J., Strawderman, M. S., Maclean, K. N., Evans, J., 
and Strupp, B. J. (2008) Evidence for social anxiety and impaired social cognition 
in a mouse model of Fragile X syndrome, Behavioral Neuroscience 122, 293-
300. 
 
26. Moon, J., Beaudin, A. E., Verosky, S., Driscoll, L. L., Weiskopf, M., Levitsky, D. 
A., Crnic, L. S., and Strupp, B. J. (2006) Attentional dysfunction, impulsivity, and 
resistance to change in a mouse model of fragile X syndrome, Behav Neurosci 
120, 1367-1379. 
 
27. Koekkoek, S. K., Yamaguchi, K., Milojkovic, B. A., Dortland, B. R., Ruigrok, T. J., 
Maex, R., De Graaf, W., Smit, A. E., VanderWerf, F., Bakker, C. E., Willemsen, 
R., Ikeda, T., Kakizawa, S., Onodera, K., Nelson, D. L., Mientjes, E., Joosten, M., 
De Schutter, E., Oostra, B. A., Ito, M., and De Zeeuw, C. I. (2005) Deletion of 
FMR1 in Purkinje cells enhances parallel fiber LTD, enlarges spines, and 
attenuates cerebellar eyelid conditioning in Fragile X syndrome, Neuron 47, 339-
352. 
 
28. Nosyreva, E. D., and Huber, K. M. (2006) Metabotropic receptor-dependent long-
term depression persists in the absence of protein synthesis in the mouse model 
of fragile X syndrome, J Neurophysiol 95, 3291-3295. 
 
29. Gerfen, C. R., Herkenham, M., and Thibault, J. (1987) The neostriatal mosaic .2. 
patch-directed and matrix-directed mesostriatal dopaminergic and 
nondopaminergic systems, Journal of Neuroscience 7, 3915-3934. 
 
30. Centonze, D., Picconi, B., Gubellini, P., Bernardi, G., and Calabresi, P. (2001) 
Dopaminergic control of synaptic plasticity in the dorsal striatum, Eur J Neurosci 
13, 1071-1077. 
 
31. Gerdeman, G. L., Ronesi, J., and Lovinger, D. M. (2002) Postsynaptic 
endocannabinoid release is critical to long-term depression in the striatum, Nat 
Neurosci 5, 446-451. 
 
32. Giuffrida, A., Parsons, L. H., Kerr, T. M., de Fonseca, F. R., Navarro, M., and 
Piomelli, D. (1999) Dopamine activation of endogenous cannabinoid signaling in 
dorsal striatum, Nat. Neurosci. 2, 358-363. 
 
 74
33. Kreitzer, A. C., and Malenka, R. C. (2005) Dopamine modulation of state-
dependent endocannabinoid release and long-term depression in the striatum, J 
Neurosci 25, 10537-10545. 
 
34. Calabresi, P., Saiardi, A., Pisani, A., Baik, J. H., Centonze, D., Mercuri, N. B., 
Bernardi, G., and Borrelli, E. (1997) Abnormal synaptic plasticity in the striatum of 
mice lacking dopamine D2 receptors, J Neurosci 17, 4536-4544. 
 
35. Jones, S. R., Gainetdinov, R. R., Jaber, M., Giros, B., Wightman, R. M., and 
Caron, M. G. (1998) Profound neuronal plasticity in response to inactivation of 
the dopamine transporter, Proc Natl Acad Sci U S A 95, 4029-4034. 
 
36. Young, J. G., Kavanagh, M. E., Anderson, G. M., Shaywitz, B. A., and Cohen, D. 
J. (1982) Clinical neurochemistry of autism and associated disorders, J Autism 
Dev Disord 12, 147-165. 
 
37. Baranek, G. T., Danko, C. D., Skinner, M. L., Bailey, D. B., Jr., Hatton, D. D., 
Roberts, J. E., and Mirrett, P. L. (2005) Video analysis of sensory-motor features 
in infants with fragile X syndrome at 9-12 months of age, J Autism Dev Disord 35, 
645-656. 
 
38. Einfeld, S. L., Tonge, B. J., and Florio, T. (1994) Behavioural and emotional 
disturbance in fragile X syndrome, Am J Med Genet 51, 386-391. 
 
39. Aman, M. G., and Langworthy, K. S. (2000) Pharmacotherapy for hyperactivity in 
children with autism and other pervasive developmental disorders, J Autism Dev 
Disord 30, 451-459. 
 
40. Bartak, L., and Rutter, M. (1976) Differences between mentally retarded and 
normally intelligent autistic children, J Autism Child Schizophr 6, 109-120. 
 
41. Campbell, M., Locascio, J. J., Choroco, M. C., Spencer, E. K., Malone, R. P., 
Kafantaris, V., and Overall, J. E. (1990) Stereotypies and tardive dyskinesia: 
abnormal movements in autistic children, Psychopharmacol Bull 26, 260-266. 
 
42. Meiselas, K. D., Spencer, E. K., Oberfield, R., Peselow, E. D., Angrist, B., and 
Campbell, M. (1989) Differentiation of stereotypies from neuroleptic-related 
dyskinesias in autistic children, J Clin Psychopharmacol 9, 207-209. 
 
43. Fleckenstein, A. E., Volz, T. J., Riddle, E. L., Gibb, J. W., and Hanson, G. R. 
(2007) New insights into the mechanism of action of amphetamines, Annu Rev 
Pharmacol Toxicol 47, 681-698. 
 
44. Gainetdinov, R. R., Wetsel, W. C., Jones, S. R., Levin, E. D., Jaber, M., and 
Caron, M. G. (1999) Role of serotonin in the paradoxical calming effect of 
psychostimulants on hyperactivity, Science 283, 397-401. 
 75
 
45. Jinnah, H. A., Gage, F. H., and Friedmann, T. (1991) Amphetamine-induced 
behavioral-phenotype in a hypoxanthine guanine phosphoribosyltransferase 
deficient mouse model of lesch-nyhan syndrome, Behavioral Neuroscience 105, 
1004-1012. 
 
46. Sallinen, J., Haapalinna, A., Viitamaa, T., Kobilka, B. K., and Scheinin, M. (1998) 
D-amphetamine and L-5-hydroxytryptophan-induced behaviours in mice with 
genetically-altered expression of the alpha(2C)-adrenergic receptor subtype, 
Neuroscience 86, 959-965. 
 
47. Ventura, R., Pascucci, T., Catania, M. V., Musumeci, S. A., and Puglisi-Allegra, 
S. (2004) Object recognition impairment in Fmr1 knockout mice is reversed by 
amphetamine: involvement of dopamine in the medial prefrontal cortex, Behav 
Pharmacol 15, 433-442. 
 
48. Zupan, B., and Toth, M. (2008) Wild-type male offspring of fmr-1(+/-) mothers 
exhibit characteristics of the fragile X phenotype, Neuropsychopharmacology 33, 
2667-2675. 
 
49. Rebec, G. V., and Segal, D. S. (1980) Apparent tolerance to some aspects of 
amphetamine stereotypy with long-term treatment, Pharmacology Biochemistry 
and Behavior 13, 793-797. 
 
50. Brien, J. F., Peachey, J. E., Rogers, B. J., and Kitney, J. C. (1977) 
Amphetamine-induced stereotyped behavior and brain concentrations of 
amphetamine and its hydroxylated metabolites in mice, Journal of Pharmacy and 
Pharmacology 29, 49-50. 
 
51. Kasim, S., and Jinnah, H. A. (2002) Pharmacologic thresholds for self-injurious 
behavior in a genetic mouse model of Lesch-Nyhan disease, Pharmacology 
Biochemistry and Behavior 73, 583-592. 
 
52. Cho, A. K., Melega, W. P., Kuczenski, R., Segal, D. S., and Schmitz, D. A. (1999) 
Caudate-putamen dopamine and stereotypy response profiles after intravenous 
and subcutaneous amphetamine, Synapse 31, 125-133. 
 
53. Creese, I., and Iversen, S. D. (1974) The role of forebrain dopamine systems in 
amphetamine induced stereotyped behavior in the rat, Psychopharmacologia 39, 
345-357. 
 
54. Fowler, S. C., Birkestrand, B. R., Chen, R., Moss, S. J., Vorontsova, E., Wang, 
G., and Zarcone, T. J. (2001) A force-plate actometer for quantitating rodent 
behaviors: illustrative data on locomotion, rotation, spatial patterning, 
stereotypies, and tremor, J Neurosci Methods 107, 107-124. 
 
 76
55. Fowler, S. C., Pinkston, J. W., and Vorontsova, E. (2007) Clozapine and prazosin 
slow the rhythm of head movements during focused stereotypy induced by d-
amphetamine in rats, Psychopharmacology 192, 219-230. 
 
56. Fowler, S. C., Covington, H. E., and Miczek, K. A. (2007) Stereotyped and 
complex motor routines expressed during cocaine self-administration: results 
from a 24-h binge of unlimited cocaine access in rats, Psychopharmacology 192, 
465-478. 
 
57. Johnson, M. A., Rajan, V., Miller, C. E., and Wightman, R. M. (2006) Dopamine 
release is severely compromised in the R6/2 mouse model of Huntington's 
disease, Journal of Neurochemistry 97, 737-746. 
 
58. Kawagoe, K. T., Zimmerman, J. B., and Wightman, R. M. (1993) Principles of 
Voltammetry and Microelectrode Surface-States, Journal of Neuroscience 
Methods 48, 225-240. 
 
59. Hayashi, M. L., Rao, B. S. S., Seo, J. S., Choi, H. S., Dolan, B. M., Choi, S. Y., 
Chattarji, S., and Tonegawa, S. (2007) Inhibition of p21-activated kinase rescues 
symptoms of fragile X syndrome in mice, Proceedings of the National Academy 
of Sciences of the United States of America 104, 11489-11494. 
 
60. Mineur, Y. S., Sluyter, F., de Wit, S., Oostra, B. A., and Crusio, W. E. (2002) 
Behavioral and neuroanatomical characterization of the Fmr1 knockout mouse, 
Hippocampus 12, 39-46. 
 
61. Moy, S. S., Nadler, J. J., Young, N. B., Nonneman, R. J., Grossman, A. W., 
Murphy, D. L., D'Ercole, A. J., Crawley, J. N., Magnuson, T. R., and Lauder, J. M. 
(2009) Social approach in genetically engineered mouse lines relevant to autism, 
Genes Brain and Behavior 8, 129-142. 
 
62. Spencer, C. M., Serysheva, E., Yuva-Paylor, L. A., Oostra, B. A., Nelson, D. L., 
and Paylor, R. (2006) Exaggerated behavioral phenotypes in Fmr1/Fxr2 double 
knockout mice reveal a functional genetic interaction between Fragile X-related 
proteins, Human Molecular Genetics 15, 1984-1994. 
 
63. Yan, Q. J., Asafo-Adjei, P. K., Arnold, H. M., Brown, R. E., and Bauchwitz, R. P. 
(2004) A phenotypic and molecular characterization of the fmr1-tm1Cgr fragile X 
mouse, Genes Brain Behav 3, 337-359. 
 
64. Yan, Q. J., Rammal, M., Tranfaglia, M., and Bauchwitz, R. P. (2005) Suppression 
of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 
antagonist MPEP, Neuropharmacology 49, 1053-1066. 
 
 77
65. Zupan, B., and Toth, M. (2008) Inactivation of the Maternal Fragile X Gene 
Results in Sensitization of GABA(B) Receptor Function in the Offspring, Journal 
of Pharmacology and Experimental Therapeutics 327, 820-826. 
 
66. Fulks, J. L., O'Bryhim, B. E., Wenzel, S. K., Fowler, S. C., Vorontsova, E., 
Pinkston, J. W., Ortiz, A. N., and Johnson, M. A. (2010) Dopamine Release and 
Uptake Impairments and Behavioral Alterations Observed in Mice that Model 
Fragile X Mental Retardation Syndrome, ACS Chemical Neuroscience 1, 679-
690. 
 
67. Annangudi, S. P., Luszpak, A. E., Kim, S. H., Ren, S., Hatcher, N. G., Weiler, I. 
J., Thornley, K. T., Kile, B. M., Wightman, R. M., Greenough, W. T., and 
Sweedler, J. V. (2010) Neuropeptide Release Is Impaired in a Mouse Model of 
Fragile X Mental Retardation Syndrome, ACS Chemical Neuroscience. 
 
68. Kraft, J. C., Osterhaus, G. L., Ortiz, A. N., Garris, P. A., and Johnson, M. A. 
(2009) In vivo dopamine release and uptake impairments in rats treated with 3-
nitropropionic acid, Neuroscience 161, 940-949. 
 
69. Cooper, J. R., Bloom, F. E., and Roth, R. H. (2003) The Biochemical Basis of 
Neuropharmacology, Eighth ed., Oxford University Press, New York. 
 
70. O'Neill, C., Evers-Donnelly, A., Nicholson, D., O'Boyle, K. M., and O'Connor, J. J. 
(2009) D-2 receptor-mediated inhibition of dopamine release in the rat striatum in 
vitro is modulated by CB1 receptors: studies using fast cyclic voltammetry, 
Journal of Neurochemistry 108, 545-551. 
 
71. Ortiz, A. N., Kurth, B. J., Osterhaus, G. L., and Johnson, M. A. (2009) 
Dysregulation of intracellular dopamine stores revealed in the R6/2 mouse 
striatum., J Neurochem. 
 
72. Venton, B. J., Seipel, A. T., Phillips, P. E. M., Wetsel, W. C., Gitler, D., 
Greengard, P., Augustine, G. J., and Wightman, R. M. (2006) Cocaine increases 
dopamine release by mobilization of a synapsin-dependent reserve pool, Journal 
of Neuroscience 26, 3206-3209. 
 
73. Chiueh, C. C., and Moore, K. E. (1975) D-amphetamine-induced release of newly 
synthesized and stored dopamine from caudate-nucleus invivo, Journal of 
Pharmacology and Experimental Therapeutics 192, 642-653. 
 
74. Fischer, J. F., and Cho, A. K. (1979) Chemical-release of dopamine from striatal 
homogenates - evidence for an exchange diffusion-model, Journal of 
Pharmacology and Experimental Therapeutics 208, 203-209. 
 
75. Liang, N. Y., and Rutledge, C. O. (1982) Evidence for carrier-mediated efflux of 
dopamine from corpus striatum, Biochemical Pharmacology 31, 2479-2484. 
 78
 
76. Jones, S. R., Gainetdinov, R. R., Wightman, R. M., and Caron, M. G. (1998) 
Mechanisms of amphetamine action revealed in mice lacking the dopamine 
transporter, Journal of Neuroscience 18, 1979-1986. 
 
77. Mathews, C. K., and van Holde, K. E. (1996) Biochemistry, 2nd ed., 
Benjamin/Cummings, Menlo Park, CA. 
 
78. Paterson, N. E., Fedolak, A., Olivier, B., Hanania, T., Ghavami, A., and 
Caldarone, B. (2010) Psychostimulant-like discriminative stimulus and locomotor 
sensitization properties of the wake-promoting agent modafinil in rodents, 
Pharmacology Biochemistry and Behavior 95, 449-456. 
 
79. Walker, Q. D., Morris, S. E., Arrant, A. E., Nagel, J. M., Parylak, S., Zhou, G. Y., 
Caster, J. M., and Kuhn, C. M. (2010) Dopamine Uptake Inhibitors but Not 
Dopamine Releasers Induce Greater Increases in Motor Behavior and 
Extracellular Dopamine in Adolescent Rats Than in Adult Male Rats, Journal of 
Pharmacology and Experimental Therapeutics 335, 124-132. 
 
80. Rothman, R. B., Mele, A., Reid, A. A., Akunne, H. C., Greig, N., Thurkauf, A., 
Decosta, B. R., Rice, K. C., and Pert, A. (1991) GBR12909 antagonizes the 
ability of cocaine to elevate extracellular levels of dopamine, Pharmacology 
Biochemistry and Behavior 40, 387-397. 
 
81. Zalfa, F., Giorgi, M., Primerano, B., Moro, A., Di Penta, A., Reis, S., Oostra, B., 
and Bagni, C. (2003) The fragile X syndrome protein FMRP associates with BC1 
RNA and regulates the translation of specific mRNAs at synapses, Cell 112, 317-
327. 
 
82. Homayoun, H., Stefani, M. R., Adams, B. W., Tamagan, G. D., and Moghaddam, 
B. (2004) Functional Interaction Between NMDA and mGlu5 Receptors: Effects 
on Working Memory, Instrumental Learning, Motor Behaviors, and Dopamine 
Release, Neuropsychopharmacology 29, 1259-1269. 
 
83. Vanderklish, P. W., and Edelman, G. M. (2005) Differential translation and fragile 
X syndrome, Genes Brain and Behavior 4, 360-384. 
 
84. Chang, S., Bray, S. M., Li, Z. G., Zarnescu, D. C., He, C., Jin, P., and Warren, S. 
T. (2008) Identification of small molecules rescuing fragile X syndrome 
phenotypes in Drosophila, Nature Chemical Biology 4, 256-263. 
 
 
 
 
 
 79
CHAPTER 3 
 
DOPAMINE RELEASE AFTER CHEMOTHERAPY:  INVESTIGATING 
THE PHENOMENON KNOWN AS “CHEMOBRAIN” 
 
“Chemobrain” or “Chemofog” is a persistent decline in cognitive function 
experienced by cancer patients following chemotherapy. Studies comparing cognitive 
function before and after treatment suggest that approximately 20-30% of cancer 
patients exhibit decreased mental capacity following treatment.  Currently, the 
phenomenon is not well understood; however, it is important to develop an 
understanding of the neurological effects of chemotherapy as the survival rates of 
cancers continue to increase.  One of the drugs associated with the cognitive decline of 
chemobrain is carboplatin, which is used to treat various cancers including those of the 
gastrointestinal tract, breast, head and neck, and bladder.   
Dopamine is an abundant CNS neurotransmitter involved in cognition, 
motivation, reward, and memory.  We hypothesized that treatment with carboplatin 
impairs DA system function, potentially leading to problems with cognition.  Fast-scan 
cyclic voltammetry (FSCV) at carbon-fiber microelectrodes was used to measure 
electrically-evoked dopamine release in striatal brain slices from male Wistar rats.  The 
dosing for each of the four treatment groups was:  vehicle, 5 mg/kg, 20 mg/kg, and 60 
mg/kg.  Measurements were collected from the dorsolateral, dorsomedial, ventrolateral, 
and ventromedial quadrants of the striatum.  Treatment with carboplatin resulted in a 
dose-dependent diminishment in the release of dopamine; however, uptake was 
unaffected.  Reserve pool dopamine was quantified by sequential treatment with alpha-
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methyl-para-tyrosine (50µM), which inhibits dopamine synthesis, and amphetamine 
(20µM), which induces dopamine efflux.  The data indicate that reserve pool dopamine 
levels are unchanged by carboplatin treatment, suggesting that the release process is 
impaired.  
  
3.1 INTRODUCTION 
3.1.1  Symptoms Associated with Chemobrain 
Chemotherapy treatments come with a variety of unwanted side effects as the 
drugs work to kill the cancer cells.  As the number of cancer survivors is ever increasing 
with the development of new treatments and earlier cancer detection, the reports of 
lasting effects of chemotherapy have been rising.  One adverse effect that is being 
reported more often, especially in cases of breast cancer, treatment of cancer in 
children, and in colon cancer patients (1-3), is the alteration and decline of cognitive 
function (1, 4).  This alteration, referred to as chemobrain, has a serious impact on the 
quality of life experienced by sufferers (5-6).   
Various problems with cognitive function have been reported in cases of 
chemobrain.  These alterations include:  verbal and visual memory problems, lessened 
mental flexibility, slowed information processing speed, attention and concentration 
deficits, and troubles with motor function (5, 7).  Neuropsychological tests have shown 
that a large number of cancer patients and survivors experience altered cognitive 
function as compared to age matched control groups (1, 5, 8-9).  A study by Furguson 
et al evaluated the cognition of monozygotic twins, where one twin underwent 
chemotherapy (9).  The twin having undergone chemotherapy had significantly greater 
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cognitive complaints indicating that the cognitive deficits are due to chemotherapy and 
not simply due to aging. 
The mechanisms underlying these cognitive deficits are mostly unknown; 
however, the drugs used in chemotherapy are toxic chemicals that can damage blood 
vessles (10), potentially causing a disruption in blood flow (11), which can lead to 
ischemic stroke and cognitive disruption.  The chemo drugs may also cause problems 
with cognition by causing direct injury to neurons leading to an alteration in 
neurotransmitter function.   
 
3.1.2  Chemotherapeutics Associated with Chemobrain 
With a wide variety of chemotherapeutic agents now available to those suffering 
with cancer, an increase in the occurrence of cognitive decline has been seen as 
reviewed in many articles (4, 12-13).   Since the principal mechanism of 
chemotheraputics involves either cell apoptosis or cell growth/division inhibition, it is not 
surprising that many of these agents are associated with chemobrain in patients.  Some 
of the drugs that have been associated with chemobrain include tamoxifen (14), CAF 
(cyclophosphamide, doxorubicin and fluorouracil) (10, 15), CMF (cyclophosphamide, 
methotrexate and fluorouracil) (10, 16-17), as well as carboplatin (16, 18-19). 
There has been controversy over whether or not chemobrain is a real 
neurological condition (14, 20-22).  However, after the compilation of many studies, 
Argyriou et al determined that long term decline in cognition due to chemotherapy is real 
(12).  The apparent problem for the acceptance of chemobrain is the development an 
objective means of evaluating cognitive function before and after chemotherapy.  The 
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use of animal studies allows for the direct measurement of the effects of chemotherapy 
on neurotransmitters compared to experimental controls, which can then lead to 
therapeutic treatment plans for human sufferers.   
 
3.1.3  Carboplatin 
Carboplatin (cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)), depicted 
Figure 1, was developed in the 1980’s and has been used in treatment in a wide variety 
of cancers including:  head and neck, breast, ovarian, bladder, colon and others (23-
27).  The popularity of the drug increased as trial studies showed a significantly lower 
amount of side effects compared to cisplatin (28-29).  The ability of carboplatin to cross 
the blood brain barrier could be a key to its role in cognition deficits after therapy due to 
damage of neurons from its presence in the brain.  Studies have shown that 
Carboplatin, in combination with other chemotherapeutic drugs, is associated with the 
occurrence of cognitive decline (16, 30-31).  
 
Figure 1.  The structure of Carboplatin. 
 
3.1.4  Current Treatments 
Currently there are a few treatments that have shown some relief from the 
cognitive decline experienced by those experiencing chemobrain.  One treatment that 
has had some successes is the use of recombinant human erythropoietin, which 
increases hemoglobin levels (32).  An improvement in cognitive function and attention 
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has also been seen with treatments using the psychostimulant methylphenidate (33-35). 
A study by Mar Fan et al, however, evaluated the effects of methylphenidate on 
cognitive scores and verbal learning scores in women.  The study found no significant 
improvement in the cognitive function of the methylphenidate group compared to the 
placebo group, indicating that methylphenidate had no major effect on cognitive function 
(66).     
Methylphenidate increases extracellular levels of dopamine by binding to the 
dopamine transporter and blocking dopamine uptake (36-38).  The effectiveness of a 
dopamine uptake inhibitor in the treatment of chemobrain led us to the hypothesis that 
damage is done to the dopaminergic system in chemobrain.  Thus, the investigation of 
the effects of chemotherapy on dopamine release and uptake are well-justified.   
Another drug used for treatment of cognitive impairments associated with 
chemobrain is modafinil, a wake-promoting drug.  The benefit of utilizing modafinil is 
that it has a lower abuse potential compared to methylphenidate.  In a study by Lundorff 
et al a double blind study was carried out for 8 days administering 200 mg doses of 
modafinil or placebo (39).  The group receiving the modafinil reported a significant 
improvement in attention and psychomotor speed compared to the placebo group. In a 
separate study by Kohli et al it was also found that administration of modafinil enhanced 
memory and attention skills in cancer patients (40). 
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3.1.5  Previous Animal Studies 
 Few animals studies designed to assess the effects of admininistration of 
chemotherapeutic agents on neurological function have been published.  One study 
performed by Mustafa et al. evaluated the effects of 5-fluorouracil (5-Fu), a common 
drug used in adjuvant chemotherapy, on spatial working memory and the proliferation of 
neurons in adult male Lister-hooded rats (41).  They found that there was decline in the 
exploratory time spent by the 5-Fu treated rats when they were placed in a novel 
location.  They also showed that the proliferating cell counts were unaffected by the 
administration of 5-Fu, however, the levels of brain-derived neurotrophic factor (BDNF), 
a protein necessary for the survival of newborn neurons and their maturation, was 
decreased in the 5-Fu rats compared to the vehicle treated rats.   
 Joshi et al. performed a study evaluating the effects of doxorubicin administered 
to mice to evaluate the oxidative stress caused by chemotherapy, which could lead to 
cognitive decline (42).  Male B6C3 mice were dosed with either doxorubicin or saline by 
i.p. injection.  The study found that there was a significant decrease in the GSH/GSSG 
ratio, a ratio that is indicative of oxidative stress, in the brains of the doxorubicin treated 
mice compared to vehicle treated mice.  It was also shown that there were significant 
increases in glutathione-S-transferase (GST), glutathione peroxidase (GPx) and 
glutathione reductase (GR), which also indicates an increase in oxidative stress which 
may contribute to the neurological problems experienced by patients receiving or who 
have received chemotherapy.   
 In another mouse study, C57 mice were dosed with 5FU and methotrexate.  After 
evaluation of the animal learning and memory skills with a after chemotherapy 
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administration for three weeks, it was shown that the chemotherapeutic receiving mice 
had learning and memory impairments compared to the mice receiving saline injections 
(43). 
 Dietrich et al evaluated the effects of chemotherapeutic agents on CBA mice 
after treatment with BCNU (Carmustine), cisplatin or cytrabine injections.  When 
compairing the mice receiving chemotherapeutic injections to the saline injected mice, it 
was found that there was an increase in cell death and decreased cell division in the 
following locations in the brain compared to the drug free mice: the subventricular zone, 
the dentate gyrus of the hippocampus and in the corpus callosum (44).  A negative 
effect of methotrexate on cell proliferation in the hippocampus has also been shown in 
rats dosed with methotrexate (45). 
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3.2 EXPERIMENTAL PROCEDURES 
 
3.2.1 Materials 
 Carboplatin, alpha-methyl-para-tyrosine and D-amphetamine were purchased 
from Sigma-Aldrich (St. Louis, MO, USA).  All other reagents were purchased from 
Sigma Aldrich (St. Louis, MO, USA) unless otherwise noted. 
 
3.2.2 Animals 
 Male Wistar rats were purchased from Charles River (Wilmington, MA, USA) and 
were housed in the animal care unit at the University of Kansas.  Animals were allowed 
unrestricted access to food and water and a 12 hour light-dark cycle was used.  The 
Institutional Animal Care and Use committee approved all procedures prior to 
experimentation.  
 
3.2.3 Chemotherapy Administration 
 Solutions containing carboplatin dissolved in biological saline were made in 
concentrations of 2.5 mg/mL, 15 mg/mL and 26.6 mg/mL.  Male Wistar rats were given 
doses of carboplatin by intravenous (IV) injections.  Four experimental groups, 
consisting of two rats each, received one of the following doses of carboplatin: 0 mg/kg, 
5.0 mg/kg, 20.0 mg/kg, and 60 mg/kg.  Injections were given through the tail vein once a 
week for four consecutive weeks. 
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3.2.4 Brain Slice Preparation 
A previously describe procedure was used to prepare brain slices (46).  To 
summarize the procedure, rats were decapitated using a guillotine after being 
anesthetized by isoflurane inhalation in a closed chamber.  After immediate removal 
from the skull, the brain was immediately placed in a beaker with ice-cold, oxygenated 
artificial cerebrospinal fluid (aCSF).  The aCSF solution was made to contain the 
following concentrations: 2.5 mM KCl, 126 mM NaCl, 1.2 mM NaH2PO4, 25 mM 
NaHCO3, 2.4 mM CaCl2, 1.2 mM MgCl2, 20 mM HEPES, 11 mM D-glucose.  The pH 
was then adjusted to the physiological pH of 7.4.  In order to provide a constant supply 
of oxygen to the tissue, the solution was oxygenated with 95% O2/5% CO2 through 
bubbling.  The brain tissue was cooled in the aCSF solution for one minute prior to 
bisection.  One half of the brain was glued to a plate with a small block of agar also 
glued to the plate for support while slicing the tissue.  300 µm thick coronal slices 
containing the striatum were made using a vibratome (Leica, Wetzlar, Germany).  The 
slices were then placed in a perfusion chamber and equilibrated for 60 minutes by a 
continuous flow of oxygenated aCSF heated to 34 ºC.   Slice exposure to αMPT and 
AMPH was carried out by switching the aCSF flow to a reservoir containing the 50 µM 
αMPT.  After diminishing DA release a solution containing 50 µM αMPT and 20 µM 
AMPH was used to cause DA efflux. 
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3.2.5  FSCV to Detect Dopamine Release in Brain Slices 
 Carbon fiber microelectrodes, 7 µm in diameter and cut to 30 µm in length, were 
fabricated following a previously described protocol (47).  To summarize, a single 
carbon fiber (Goodfellow Cambridge Ltd, Huntingdon, UK) was aspirated by vacuum 
pump through a 4 inch glass capillary tube (1.2 mm outer diameter, 0.68 mm inner 
diameter, A-M Systems, Carlsborg, WA, USA).  To create a glass seal around the 
carbon fiber, the capillary was pulled using a heated coil puller (Narishige International 
USA, East Meadow, NY, USA).  The electrodes were cut to length using a scalpel under 
a microscope and the glass seal was reinforced by dipping the electrode tips into epoxy 
resin (EPON resin 815C, EPIKURE 3234 curing agent, Miller-Stephenson, Danbury, 
CT, USA), rinsing the excess resin with toluene, and cured at 100 ºC for one hour.  
Potassium acetate was used to back-fill the electrode in order to establish an electrical 
connection between the carbon fiber and an inserted silver wire.   
 The carbon fiber microelectrodes were calibrated prior to use by exposure to a 
known concentration of dopamine in a flow cell.  The carbon fiber was positioned in the 
brain slice using micromanipulators under a microscope such that the tip of the 
electrode was approximately 100 µm below the surface of the brain slice and between 
two stimulating electrodes.  A triangular waveform was applied to the carbon fiber 
microelectrode beginning at -0.4 V scanning up to +1.0 V and back down to -0.4 V at a 
scan rate of 300 V/sec and an update rate of 10 Hz.  The voltammetry data was 
collected using an Ag/AgCl reference electrode.  Data was collected in this manner in 
four different locations in each of the four quadrants of the striatum.  The stimulating 
electrodes were made in house by gluing two tungsten electrodes (A-M Systems Inc, 
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Carlsborg, WA, USA) and adjusting the distance of the tips using heat shrink (3M 
Electronics, Austin, TX, USA) until they were 200 µM apart.  A single biphasic 
stimulation pulse (60 Hz, 4 msec pulse width, 350 µA) was used to evoke dopamine 
release.  The current was measured at the maximum dopamine oxidation potential, 
which occurs at about +0.6 V versus a Ag/AgCl reference.  Using the predetermined 
calibration factor for each electrode, the maximum dopamine release was calculated.   
 To evaluate DA efflux, single pulses were applied every five minutes while the 
slice was exposed to 50 µM αMPT until DA release diminished.  Once DA release 
disappeared, 20 µM AMPH was added to the aCSF with the 50 µM αMPT.  DA efflux 
caused by AMPH exposure was detected over 25 minutes without the use of electrical 
stimulation.  An update rate of 5 Hz was used for the 25 minute file in order to limit to file 
size and not exceed memory limitations (48).   
 
3.2.6  Data Analysis 
 Data was analyzed following a similar approach previously used (46).  Modeling 
software written by R.M. Wightman (University of North Carolina, Chapel Hill, NC) was 
used to evaluate stimulated release plots.  By modeling the plots, parameters 
associated with the kinetics of dopamine release and uptake were determined, including 
dopamine per pulse, [DA]p, which is the peak dopamine release corrected for electrode 
performance and uptake, Vmax, the maximum rate of dopamine uptake, and KM, 
dopamine concentration at ½Vmax.   
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3.3 RESULTS 
 
3.3.1 Peak Stimulated Dopamine Release in the Striatum 
 Peak stimulated DA release data was collected from the dorsolateral (DL), 
dorsomedial (DM), ventrolateral (VL), and ventromedial (VM) quadrants of the striatum 
and are shown in Figure 2.  Four data points were collected from each quadrant and 
averaged together.  Our investigation of the role of DA release in chemobrain revealed 
a significant dose effect in all regions of the striatum (p=0.0002, F3,53 = 7.79, 2-way 
ANOVA, n = 4 to 5).   There were no differences seen within a dose between the 
different quadrants of the striatum.   
 
 
 
Figure 2.  Maximum DA release upon stimulation after chemotherapy.  Peak release data is shown for 
each dose in all four quadrants of the striatum.   
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3.3.2 Modeled Striatal Dopamine Release  
 The data collected was modeled using software to obtain additional information 
about the effects of carboplatin treatment on DA release in the striatum.  Dopamine per 
pulse, [DA]p, which is the peak dopamine release corrected for electrode performance 
and uptake, also showed a significant dose effect across all regions of the striatum 
(p=0.0025, F3,52 = 5.45, 2-way ANOVA, n = 4 to 5) and is shown in Figure 3.  There 
was no effect seen within a dose across the different regions of the striatum.   
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Figure 3.  Dopamine per pulse data in the four quadrants of the striatum.  A significant dose effect was 
seen (p=0.0025, F3,52 = 5.45, 2-way ANOVA, n = 4 to 5).   
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Vmax was also determined from modeling the data also gave information about 
the uptake of dopamine after treatment with carboplatin.  Data analysis showed that 
there was no difference in the uptake rates between the different doses of carboplatin, 
Figure 4.  There was also no difference in the uptake rates between the different 
regions of the brain within a dose.  
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Figure 4.  DA uptake data.  Vmax data for each dose of carboplatin throughout the striatum (n = 4 to 5).   
 
 3.3.3 Dopamine Reserve Pools 
 We also evaluated the reserve pools of DA in the DL region of the striatum.  After 
the stimulated DA release data was collected, the electrode was placed in the 
dorsolateral region and the slice was exposed to αMPT to inhibit DA synthesis.  The 
slice was stimulated until the DA release was eliminated.  The raw data (Figure 5) 
shows how we began with a good DA signal and how αMPT caused the elimination of 
DA release and the efflux of DA caused by the addition of AMPH.   
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Figure 5.  Raw data showing DA release, the elimination of DA release by αMPT and the efflux of DA 
caused by AMPH.  Cyclic voltammograms show next to each plot verify the detection of DA. 
 
 The maximum amount of DA released by efflux due to AMPH exposure was 
calculated based on the electrode calibration and the peak current from the AMPH 
exposure data.  The DA efflux data for each carboplatin dose group was averaged and 
is shown in Figure 6.  There was no difference observed in the amount of reserve pool 
DA efflux due to AMPH between the different doses of carboplatin.      
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Figure 6.  DA efflux caused by AMPH.  Stimulated DA release was eliminated by slice exposure to αMPT 
followed by AMPH, which caused DA efflux.  The maximum DA concentration caused by AMPH is shown 
for each dose group (n=3).  
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3.4 DISCUSSION  
 In this study the effects of carboplatin chemotherapy on the DA system 
were examined.  We evaluated DA release in each of the four main quadrants of the 
striatum because they are associated with different areas of cognition.  The dorsal 
region is commonly associated with motor control as well as motivation and reward (38, 
49), while the ventral region is associated with learning memory (50).  Since the 
cognitive decline is experienced in chemobrain, it was important to evaluate the effects 
of carboplatin on each region to determine if one region was more strongly affected than 
others.  Our results showed that there was a generalized effect on DA release 
throughout the striatum, finding no difference between any regions within a dose.    
The stimulated DA release in brain slices after carboplatin injections showed a 
significant dose effect on the amount of DA released upon stimulation in the striatum.  
We have also shown a significant dose effect on dopamine per pulse.  The higher doses 
of carboplatin having a negative influence on DA release could explain the higher 
incidence of chemobrain associated with higher doses of chemotherapy (31, 51).  
Moreover, we found that Vmax was unchanged between the doses, which indicates that 
carboplatin treatment does not cause alterations in the function of DAT (52).   
 Stimulated DA release causes the exocytosis of DA from the readily releasable 
pool (RRP).  The RRP only contributes about 1-2% of the total DA vesicles in the 
presynaptic terminal Since DA release (53).  As the RRP is depleted, the recycling pool 
is mobilized (54-56).  The largest pool of DA is the reserve pool, which makes up 80-
90% of the DA stores and is thought to be mobilized under conditions of high synaptic 
activity (53, 57-58).  Evidence also suggests that this pool can also be mobilized 
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experimentally by intense electrical stimulation (56, 59-62).  Reserve pools can also be 
examined through the use of pharmacological agents by first depleating the RRP and 
recycling pool by inhibiting DA synthesis in the presynaptic terminal by first exposing the 
slice to αMPT and stimulating the slice until DA release was depleted (48).  Once the 
stimulated dopamine release was eliminated, AMPH was added to the perfusion aCSF 
to cause DA efflux by reverse transport, which is caused by allosteric translocation of 
the DAT such that dopamine transport into the extracellular space is facilitated (63-65).  
We were unable to detect any differences in reserve pool dopamine measure by 
maximum current after DA efflux caused by AMPH; however, more experiments are 
necessary to confirm this finding.  Nevertheless, the finding that DA reserve pools are 
unchanged implies that the decrease in DA release with increasing carboplatin dose 
may be due to an alteration in the RRP release mechanism.   
 Our findings may also provide insight into the reason why methylphenidate has 
been shown to be a useful treatment in some chemobrain patients (35).  
Methylphenidate causes an increase in extracellular DA which helps alleviate symptoms 
associated with decreased DA release.  Collectively, these data suggest that 
enhancement of dopamine release may represent a viable therapeutic option in the 
treatment of cognitive deficits associated with chemobrain.   
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3.5 CONCLUDING REMARKS 
These initial studies have investigated the effects of a commonly used 
chemotherapeutic agent, carboplatin, on DA release in the striatum.  The results here 
have shown a significant dose effect of carboplatin on stimulated DA release in all 
regions of the striatum.  Our results also indicate that reserve pools of DA are unaltered 
by carboplatin.  This work and future work in this area have the potential to reveal 
therapeutic treatment strategies that could ultimately aid in the management and 
treatment of the cognitive impairments associated with chemobrain in patients.   We are 
currently pursuing the further investigation of other chemotherapeutics on DA release 
and the evaluation of the effects of the drugs on total DA content as well.    
 
ACKNOWLEDGEMENTS 
 We thank the National Science Foundation REU program for financial support. 
This work was funded in part by the R.N. Adams Institute for Bioanalytical Chemistry. 
 98
3.6 REFERENCES 
 
 
1. Wefel, J. S., Saleeba, A. K., Buzdar, A. U., and Meyers, C. A. (2010) Acute and 
Late Onset Cognitive Dysfunction Associated With Chemotherapy in Women 
With Breast Cancer, Cancer 116, 3348-3356. 
 
2. Winick, N. (2010) Neurocognitive outcome in survivors of pediatric cancer, Curr 
Opin Pediatr. 
 
3. Vardy, J., and Tannock, I. (2007) Cognitive function after chemotherapy in adults 
with solid tumours, Crit Rev Oncol Hematol 63, 183-202. 
 
4. Marin, A. P., Sanchez, A. R., Arranz, E. E., Aunon, P. Z., and Baron, M. G. 
(2009) Adjuvant Chemotherapy for Breast Cancer and Cognitive Impairment, 
Southern Medical Journal 102, 929-934. 
 
5. Boykoff, N., Moieni, M., and Subramanian, S. K. (2009) Confronting chemobrain: 
an in-depth look at survivors' reports of impact on work, social networks, and 
health care response, J Cancer Surviv 3, 223-232. 
 
6. Grober, S. E. (2002) Resources for treatment of chemotherapy-related cognitive 
difficulty, Cancer Pract 10, 216-218. 
 
7. Nelson, C. J., Nandy, N., and Roth, A. J. (2007) Chemotherapy and cognitive 
deficits: mechanisms, findings, and potential interventions, Palliat Support Care 
5, 273-280. 
 
8. Ahles, T. A., Saykin, A. J., Furstenberg, C. T., Cole, B., Mott, L. A., Skalla, K., 
Whedon, M. B., Bivens, S., Mitchell, T., Greenberg, E. R., and Silberfarb, P. M. 
(2002) Neuropsychologic impact of standard-dose systemic chemotherapy in 
long-term survivors of breast cancer and lymphoma, J Clin Oncol 20, 485-493. 
 
9. Ferguson, R. J., McDonald, B. C., Saykin, A. J., and Ahles, T. A. (2007) Brain 
structure and function differences in monozygotic twins: possible effects of breast 
cancer chemotherapy, J Clin Oncol 25, 3866-3870. 
 
10. Ahles, T. A., and Saykin, A. (2001) Cognitive effects of standard-dose 
chemotherapy in patients with cancer, Cancer Investigation 19, 812-820. 
 
11. Ramassamy, C., Averill, D., Beffert, U., Bastianetto, S., Theroux, L., Lussier-
Cacan, S., Cohn, J. S., Christen, Y., Davignon, J., Quirion, R., and Poirier, J. 
(1999) Oxidative damage and protection by antioxidants in the frontal cortex of 
Alzheimer's disease is related to the apolipoprotein E genotype, Free Radical 
Biology and Medicine 27, 544-553. 
 
 99
12. Argyriou, A. A., Assimakopoulos, K., Iconomou, G., Giannakopoulou, F., and 
Kalofonos, H. P. (2011) Either Called "Chemobrain'' or "Chemofog,'' the Long-
Term Chemotherapy-Induced Cognitive Decline in Cancer Survivors Is Real, 
Journal of Pain and Symptom Management 41, 126-139. 
 
13. Taillibert, S., Voillery, D., and Bernard-Marty, C. (2007) Chemobrain: is systemic 
chemotherapy neurotoxic?, Current Opinion in Oncology 19, 623-627. 
 
14. van Dam, F. S., Schagen, S. B., Muller, M. J., Boogerd, W., vd Wall, E., 
Droogleever Fortuyn, M. E., and Rodenhuis, S. (1998) Impairment of cognitive 
function in women receiving adjuvant treatment for high-risk breast cancer: high-
dose versus standard-dose chemotherapy, J Natl Cancer Inst 90, 210-218. 
 
15. Wieneke, M. H., and Dienst, E. R. (1995) Neuropsychological assessment of 
cognitive-functioning following chemotherapy for breast-cancer, Psycho-Oncol. 4, 
61-66. 
 
16. Schagen, S. B., Muller, M. J., Boogerd, W., Rosenbrand, R. M., van Rhijn, D., 
Rodenhuis, S., and van Dam, F. S. (2002) Late effects of adjuvant chemotherapy 
on cognitive function: a follow-up study in breast cancer patients, Ann Oncol 13, 
1387-1397. 
 
17. Schagen, S. B., van Dam, F., Muller, M. J., Boogerd, W., Lindeboom, J., and 
Bruning, P. F. (1999) Cognitive deficits after postoperative adjuvant 
chemotherapy for breast carcinoma, Cancer 85, 640-650. 
 
18. Schagen, S. B., Muller, M. J., Boogerd, W., Mellenbergh, G. J., and van Dam, F. 
(2006) Change in cognitive function after chemotherapy: a prospective 
longitudinal study in breast cancer patients, Journal of the National Cancer 
Institute 98, 1742-1745. 
 
19. Hensley, M. L., Correa, D. D., Thaler, H., Wilton, A., Venkatraman, E., Sabbatini, 
P., Chi, D. S., Dupont, J., Spriggs, D., and Aghajanian, C. (2006) Phase I/II study 
of weekly paclitaxel plus carboplatin and gemcitabine as first-line treatment of 
advanced-stage ovarian cancer: pathologic complete response and longitudinal 
assessment of impact on cognitive functioning, Gynecol Oncol 102, 270-277. 
 
20. Vardy, J., and Dhillon, H. (2010) The fog hasn't lifted on "chemobrain" yet: 
ongoing uncertainty regarding the effects of chemotherapy and breast cancer on 
cognition, Breast Cancer Research and Treatment 123, 35-37. 
 
21. Zukerman, J. M., Guidotti, L. M., Hook, J. N., Stebbins, G. T., Gregory, S. A., and 
Han, S. (2010) Effects of Chemotherapy on Cognition and Quality of Life in Older 
Adults with Cancer, Clin. Neuropsychol. 24, 615-615. 
 
 100 
22. Hermelink, K., Untch, M., Lux, M. P., Kreienberg, R., Beck, T., Bauerfeind, I., and 
Munzel, K. (2007) Cognitive function during neoadjuvant chemotherapy for 
breast cancer: results of a prospective, multicenter, longitudinal study, Cancer 
109, 1905-1913. 
 
23. Eisenberger, M., Van Echo, D., and Aisner, J. (1989) Carboplatin: the experience 
in head and neck cancer, Semin Oncol 16, 34-41. 
 
24. Gray, H., Mandel, L., Schaad, D., Wolf, F., and Goff, B. (2010) "Chemobrain" in 
ovarian cancer: A prospective study of cognitive function and quality of life in 
women undergoing chemotherapy, Gynecologic Oncology 116, 60. 
 
25. Kavanagh, J. J., and Nicaise, C. (1989) Carboplatin in refractory epithelial 
ovarian cancer, Semin Oncol 16, 45-48. 
 
26. Coughlin, C. T., and Richmond, R. C. (1989) Biologic and clinical developments 
of cisplatin combined with radiation - concepts, utility, projections for new trials, 
and the emergence of carboplatin, Seminars in Oncology 16, 31-43. 
 
27. Wagstaff, A. J., Ward, A., Benfield, P., and Heel, R. C. (1989) Carboplatin - a 
preliminary review of its pharmacodynamic and pharmacokinetic properties and 
therapeutic efficacy in the treatment of cancer, Drugs 37, 162-190. 
 
28. Calvert, A. H., Harland, S. J., Newell, D. R., Siddik, Z. H., Jones, A. C., 
McElwain, T. J., Raju, S., Wiltshaw, E., Smith, I. E., Baker, J. M., Peckham, M. 
J., and Harrap, K. R. (1982) Early clinical-studies with cis-diammine-1,1-
cyclobutane dicarboxylate platinum-II, Cancer Chemotherapy and Pharmacology 
9, 140-147. 
 
29. Siddik, Z. H., Newell, D. R., Boxall, F. E., and Harrap, K. R. (1987) The 
comparative pharmacokinetics of carboplatin and cisplatin in mice and rats, 
Biochem Pharmacol 36, 1925-1932. 
 
30. Schagen, S. B., Hamburger, H. L., Muller, M. J., Boogerd, W., and van Dam, F. 
S. (2001) Neurophysiological evaluation of late effects of adjuvant high-dose 
chemotherapy on cognitive function, J Neurooncol 51, 159-165. 
 
31. Schagen, S. B., Muller, M. J., Boogerd, W., Mellenbergh, G. J., and van Dam, F. 
S. (2006) Change in cognitive function after chemotherapy: a prospective 
longitudinal study in breast cancer patients, J Natl Cancer Inst 98, 1742-1745. 
 
32. Gabrilove, J. L., Cleeland, C. S., Livingston, R. B., Sarokhan, B., Winer, E., and 
Einhorn, L. H. (2001) Clinical evaluation of once-weekly dosing of epoetin alfa in 
chemotherapy patients: improvements in hemoglobin and quality of life are 
similar to three-times-weekly dosing, J Clin Oncol 19, 2875-2882. 
 
 101 
33. Rozans, M., Dreisbach, A., Lertora, J. J., and Kahn, M. J. (2002) Palliative uses 
of methylphenidate in patients with cancer: a review, J Clin Oncol 20, 335-339. 
 
34. Sood, A., Barton, D. L., and Loprinzi, C. L. (2006) Use of methylphenidate in 
patients with cancer, Am J Hosp Palliat Care 23, 35-40. 
 
35. Meyers, C. A., Weitzner, M. A., Valentine, A. D., and Levin, V. A. (1998) 
Methylphenidate therapy improves cognition, mood, and function of brain tumor 
patients, Journal of Clinical Oncology 16, 2522-2527. 
 
36. Challman, T. D., and Lipsky, J. J. (2000) Methylphenidate: its pharmacology and 
uses, Mayo Clin Proc 75, 711-721. 
 
37. Hurd, Y. L., and Ungerstedt, U. (1989) In vivo neurochemical profile of dopamine 
uptake inhibitors and releasers in rat caudate-putamen, Eur J Pharmacol 166, 
251-260. 
 
38. Volkow, N. D., Wang, G. J., Fowler, J. S., Gatley, S. J., Logan, J., Ding, Y. S., 
Hitzemann, R., and Pappas, N. (1998) Dopamine transporter occupancies in the 
human brain induced by therapeutic doses of oral methylphenidate, Am J 
Psychiatry 155, 1325-1331. 
 
39. Lundorff, L. E., Jonsson, B. H., and Sjogren, P. (2009) Modafinil for attentional 
and psychomotor dysfunction in advanced cancer: a double-blind, randomised, 
cross-over trial, Palliat Med 23, 731-738. 
 
40. Kohli, S., Fisher, S. G., Tra, Y., Adams, M. J., Mapstone, M. E., Wesnes, K. A., 
Roscoe, J. A., and Morrow, G. R. (2009) The effect of modafinil on cognitive 
function in breast cancer survivors, Cancer 115, 2605-2616. 
 
41. Mustafa, S., Walker, A., Bennett, G., and Wigmore, P. M. (2008) 5-Fluorouracil 
chemotherapy affects spatial working memory and newborn neurons in the adult 
rat hippocampus, Eur J Neurosci 28, 323-330. 
 
42. Joshi, G., Aluise, C. D., Cole, M. P., Sultana, R., Pierce, W. M., Vore, M., St 
Clair, D. K., and Butterfield, D. A. (2010) Alterations in brain antioxidant enzymes 
and redox proteomic identification of oxidized brain proteins induced by the anti-
cancer drug adriamycin: implications for oxidative stress-mediated chemobrain, 
Neuroscience 166, 796-807. 
 
43. Winocur, G., Vardy, J., Binns, M. A., Kerr, L., and Tannock, I. (2006) The effects 
of the anti-cancer drugs, methotrexate and 5-fluorouracil, on cognitive function in 
mice, Pharmacol Biochem Behav 85, 66-75. 
 
 102 
44. Dietrich, J., Han, R., Yang, Y., Mayer-Proschel, M., and Noble, M. (2006) CNS 
progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in 
vitro and in vivo, J Biol 5, 22. 
 
45. Seigers, R., Schagen, S. B., Beerling, W., Boogerd, W., van Tellingen, O., van 
Dam, F. S., Koolhaas, J. M., and Buwalda, B. (2008) Long-lasting suppression of 
hippocampal cell proliferation and impaired cognitive performance by 
methotrexate in the rat, Behav Brain Res 186, 168-175. 
 
46. Johnson, M. A., Rajan, V., Miller, C. E., and Wightman, R. M. (2006) Dopamine 
release is severely compromised in the R6/2 mouse model of Huntington's 
disease, Journal of Neurochemistry 97, 737-746. 
 
47. Kawagoe, K. T., Zimmerman, J. B., and Wightman, R. M. (1993) Principles of 
Voltammetry and Microelectrode Surface-States, Journal of Neuroscience 
Methods 48, 225-240. 
 
48. Ortiz, A. N., Kurth, B. J., Osterhaus, G. L., and Johnson, M. A. (2009) 
Dysregulation of intracellular dopamine stores revealed in the R6/2 mouse 
striatum., J Neurochem. 
 
49. Palmiter, R. D. (2008) Dopamine signaling in the dorsal striatum is essential for 
motivated behaviors: lessons from dopamine-deficient mice, Ann N Y Acad Sci 
1129, 35-46. 
 
50. Jocham, G., Klein, T. A., and Ullsperger, M. (2011) Dopamine-mediated 
reinforcement learning signals in the striatum and ventromedial prefrontal cortex 
underlie value-based choices, J Neurosci 31, 1606-1613. 
 
51. Park, S. B., Goldstein, D., Lin, C. S. Y., Krishnan, A. V., Friedlander, M. L., and 
Kiernan, M. C. (2009) Acute Abnormalities of Sensory Nerve Function 
Associated With Oxaliplatin-Induced Neurotoxicity, Journal of Clinical Oncology 
27, 1243-1249. 
 
52. Zhu, J., Bardo, M. T., Bruntz, R. C., Stairs, D. J., and Dwoskin, L. P. (2007) 
Individual differences in response to novelty predict prefrontal cortex dopamine 
transporter function and cell surface expression, Eur J Neurosci 26, 717-728. 
 
53. Rizzoli, S. O., and Betz, W. J. (2005) Synaptic vesicle pools, Nature Reviews 
Neuroscience 6, 57-69. 
 
54. Harata, N., Ryan, T. A., Smith, S. J., Buchanan, J., and Tsien, R. W. (2001) 
Visualizing recycling synaptic vesicles in hippocampal neurons by FM 1-43 
photoconversion, Proceedings of the National Academy of Sciences of the 
United States of America 98, 12748-12753. 
 
 103 
55. Kuromi, H., and Kidokoro, Y. (2003) Two synaptic vesicle pools, vesicle 
recruitment and replenishment of pools at the Drosophila neuromuscular 
junction, Journal of Neurocytology 32, 551-565. 
 
56. Richards, D. A., Guatimosim, C., Rizzoli, S. O., and Betz, W. J. (2003) Synaptic 
vesicle pools at the frog neuromuscular junction, Neuron 39, 529-541. 
 
57. Neves, G., and Lagnado, L. (1999) The kinetics of exocytosis and endocytosis in 
the synaptic terminal of goldfish retinal bipolar cells, Journal of Physiology-
London 515, 181-202. 
 
58. Zucker, R. S., and Regehr, W. G. (2002) Short-term synaptic plasticity, Annual 
Review of Physiology 64, 355-405. 
 
59. Heien, M. L., and Wightman, R. M. (2006) Phasic dopamine signaling during 
behavior, reward, and disease states, CNS Neurol Disord Drug Targets 5, 99-
108. 
 
60. Ortiz, A. N., Kurth, B. J., Osterhaus, G. L., and Johnson, M. A. (2010) 
Dysregulation of intracellular dopamine stores revealed in the R6/2 mouse 
striatum, Journal of Neurochemistry 112, 755-761. 
 
61. Ortiz, A. N., Oien, D. B., Moskovitz, J., and Johnson, M. A. (2011) Quantification 
of reserve pool dopamine in methionine sulfoxide reductase a null mice, 
Neuroscience 177, 223-229. 
 
62. Venton, B. J., Seipel, A. T., Phillips, P. E., Wetsel, W. C., Gitler, D., Greengard, 
P., Augustine, G. J., and Wightman, R. M. (2006) Cocaine increases dopamine 
release by mobilization of a synapsin-dependent reserve pool, J Neurosci 26, 
3206-3209. 
 
63. Floor, E., and Meng, L. H. (1996) Amphetamine releases dopamine from 
synaptic vesicles by dual mechanisms, Neuroscience Letters 215, 53-56. 
 
64. Jones, S. R., Gainetdinov, R. R., Wightman, R. M., and Caron, M. G. (1998) 
Mechanisms of amphetamine action revealed in mice lacking the dopamine 
transporter, Journal of Neuroscience 18, 1979-1986. 
 
65. Sulzer, D., Maidment, N. T., and Rayport, S. (1993) Amphetamine and other 
weak bases act to promote reverse transport of dopamine in ventral midbrain 
neurons, Journal of Neurochemistry 60, 527-535. 
 
 
 
 
 104 
66. Mar Fan, H. G., Clemons, M., Xu, W., Chemerynsky, I., Breunis, H., Braganza, 
S., and Tannock, I. F. (2008) A randomised, placebo-controlled, double-blind trial 
of the effects of d-methylphenidate on fatigue and cognitive dysfunction in 
women undergoing adjuvant chemotherapy for breast cancer, Support Care 
Cancer 16, 577-583. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 105 
CHAPTER 4 
CAGED-COMPOUNDS AND THE BRAIN: EVALUATING THE EFFECTS 
OF PHOTORELEASING GLUTAMATE ON DOPAMINE RELEASE 
 The toxic effect of too much glutamate on brain slices poses a serious limitation 
in studying the role glutamate has in neurotransmitter release and reuptake.  In this 
work an apparatus was constructed to apply a technique using glutamate with a 
photoactive protecting group in order to “uncage” glutamate by a light source as a 
method of applying a small, localized amount of glutamate on a brain slice.  A mercury 
light source with a shutter in front of the lens was used with a fiber optic to direct 
controlled pulses of light on the desired area of the slice.  The caged form of glutamate 
had no effect on the dopamine (DA) release.  HPLC analysis was used to verify the 
incidence of ”uncaging” glutamate using the Hg light source.  The “cage” byproduct also 
had no effect of DA release and was determined to be electroactive, thus making 
detection and quantification of the released glutamate possible.  This work 
demonstrates the potential utility of caged glutamate studies on determining the effect of 
glutamate on neurotransmitter release in brain slices.    
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4.1 INTRODUCTION 
The ability to administer known concentrations of biologically active agents in a 
spatially localized area has many advantages in evaluation of biological responses.  
The use of photoactive protecting groups bonded to biologically active compounds has 
become a popular way to evaluate the immediate response to the biological compound 
once the protecting group is photocleaved.  These photoprotected compounds were 
termed “caged” compounds by Kaplan et al to describe the way in which the photoactive 
protecting group will render a compound biologically inert until it is photocleaved, thus 
releasing the biological compound (1). 
 
4.1.1  Utility of Photoreleasing compounds 
Caged compounds are molecules that have had a photoactive protecting group 
placed on the molecule such that it inactivates the molecule (2).  When the caged 
compound is exposed to a specific wavelength of light, the cage will be released and 
the compound converted back into its original, active form and the inert protecting group 
(2).  Park and Givens have shown that the protecting group used as the cage in the 
caged compounds they make is biologically safe so that the caged compounds they 
produce can be used for biological applications (2).  Exposing the caged compounds to 
a certain wavelength of light for a known length of time allows for the amount released 
to be known (3).   
 
 
 
 107 
4.1.2  Previous studies using caged compounds 
The use of fast scan cyclic voltammetry (FSCV) at carbon fiber microelectrodes 
allows for the sub-second detection of neurotransmitter release and uptake in brain 
slices (4).  These release and uptake patterns can also be examined in the presence of 
various pharmacological agents; however, this usually requires that the slice be 
exposed to a drug by perfusion for an extended period of time.  This situation is often 
impractical given that continuous exposure to certain chemicals may have deleterious 
effects on cell viability.  For example, glutamate is an abundant brain neurotransmitter 
that participates in the regulation of striatal DA release (5-8).  Nevertheless, the 
excitotoxicity of glutamate makes it impractical as a perfusion agent for brain slices.   
One potential solution to the problem described is to photoactivate a caged form 
of glutamate, thereby  preventing the prolonged exposure of the tissue, and then 
measure DA release using FSCV.  A similar approach has been previously employed 
using caged DA.  Studies done by Lee et al. have shown that caged DA can be used in 
brain slices to monitor the uptake of DA by the DA transporters based on the increased 
extracellular concentration.  In one study the DA transporters were treated with cocaine, 
which acts as a DA transporter blocker (9-10).  The caged DA was hit by a pulse of light 
for a known length of time in a specific location.  By releasing the caged compound over 
a known length of time it is possible to know the concentration released (10).  The 
speed of the uptake of this DA could then be monitored.  To further investigate the 
transport of DA using the caged DA, Lee et al. showed a method of quantifying the DA 
that is released, showing that when the DA transporter was inhibited the release of 
endogenous DA was lessened by the release of the caged DA (11).  A notable 
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drawback with the approach of Lee et al. is that the caged DA used was also 
electroactive and thus required a background subtraction operation to remove the 
electrochemical signal from the uncaged DA still present in the sample (11).   
 
 
4.1.3  Types of Photoactivatable Compounds 
  
Over the last 40+ years many different compounds have been bound to photo- 
releasing groups for activation by light exposure.  Since one of the main uses for caged 
compounds is in biological applications, the primary focus has been on adding cages to 
compounds that will elicit some sort of biological response after light exposure.  Some 
of the molecules that have been “caged” include; ATP (1), calcium (12-13), DA (3), 
GABA and glutamate (2, 14-15), as well as other biological molecules.   
These caged compounds have been valuable resources in obtaining spatial and 
temporal resolution that is not allowed by total submersion or perfusion.  The light 
source can be focused on a small, specific area to probe and the release of the cage 
can be timed to detect the immediate response due to the reformation of the biologically 
active compound, which happens on a very short time scale.   
 Different molecules can be utilized as the phototrigger when synthesizing caged 
compounds.  The four most popular groups of chromophores include: 1. 2-nitrobenzyl 
(2NB), 2. benzoin, 3. p-hydroxyphenacyl (pHP), and 4. arylmethyl derivatives (16).   The 
2NB group has been a popular choice of cage; however, the time scale of photorelease 
is in the millisecond to second range (2).  Park and Givens investigated the use of pHP 
as an alternative to the use of 2NB providing a phototrigger that releases with a rate 
constant of 105 s-1 and gave a byproduct that is biologically inert (2).  Using the pHP 
group, a fast and efficient means of releasing biologically active molecules with 
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biologically inert by-products has been achieved.  The pHP group has been attached to 
glutamate and GABA, which have been successfully used in evaluating cellular 
response to the released glutamate (17-18).   
 
4.1.4  Photoactivation of pHP-Glutamate 
 Mechanistic studies have been perfomed on the pHP photoleaving group by 
Givens and Lee, which have probed the way photocleaving occurs with the pHP 
protecting group (19).  To briefly summarize the study, it was determined that the 
mechanism can be described in four primary phases once the caged compound is 
exposed to 300 nm light: 1) a triplet intermediate is formed after light exposure and the 
loss of a proton and the leaving group, 2) the diradical triplet intermediate undergoes 
bond reorganization, 3) a spirodienedione is formed along with a substrate-phenacyl 
bond cleavage, and 4) the spirodienedione undergoes hydrolysis with further bond 
reorganization (Figure 1) (19). 
 
Figure 1.  Reaction mechanism for the photocleaving of pHP-compounds (19).  Figure provided by Dr. 
Richard S. Givens.   
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4.1.5  Oxidation of 4-hydroxyphenylacetic acid (4-HPAA) 
It has been previously shown that an irreversible oxidation of 4-
hydroxyphenylacetic acid occurs at +0.95 V vs Ag/AgCl reference at a graphite 
electrode under slow scan rates (50 mV/s) (20).  Based on this previous work, it is 
hypothesized that the4-HPAA should oxidize at a carbon fiber electrode.  By utilizing 
higher scan rates it is possible that either the oxidation peak may shift as an effect of 
the scan rate.  The ability to detect the oxidation of 4-HPAA in a CV will allow for the 
simultaneous quantification of the glutamate which was photoreleased while quantifying 
DA release.   
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4.2 EXPERIMENTAL PROCEDURES 
 
4.2.1 Materials 
The p-hydroxyphenacyl glutamate (pHP-glu) was a gift from Dr. Rich Givens 
(University of Kansas, Department of Chemistry, Lawrence, KS).  All other materials 
were obtained from Sigma Aldrich (St. Louis, MO) unless otherwise specified.  
 
4.2.2 HPLC Analysis 
A gradient high performance liquid chromatography (HPLC) method was used on 
a Shimadzu Model LC 20 AD with a dual reciprocating pump and a DGV 20A3 
degasser.  The detector was a Simadzu SPD-201V UV-VIS detector set to the 
wavelengths of 220 nm and 240 nm for the detection of the pHP-glu and 4-HPAA.  The 
mobile phase reservoirs were as follows:  (A) 99% water, 1% methanol and 0.06% 
formic acid; (B) 99% methanol, 1% water and 0.06%formic acid.  Samples were injected 
by an autosampler and the gradient reached 90% B.  The flow rate was set to 0.4 
mL/min.   
 
4.2.3 HPLC sample preparation 
 Stock solutions of caged glutamate were made by dissolving caged glutamate in 
10 mL of aCSF to obtain concentrations near 10 mM.  More dilute solutions of the 
caged glutamate were made by dilution of a portion of the stock solution into aCSF to 
obtain concentrations between 100 µM and 500 µM.   
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 For verification of uncaging by our light sources, samples of the caged glutamate 
dissolved in aCSF were exposed to light from a Lambda DG-4 (Sutter Instruments, 
Novato, CA), a Mercury (Hg) lamp and natural sunlight.  After light exposure samples 
were analyzed using HPLC. 
 For analysis, calibration curves were collected of the predominant byproduct, 4-
hydroxyphenylacetic acid, and the caged glutamate each in aCSF.  The samples of 
caged glutamate exposed to the different light sources were then compared to the two 
calibration curves to verify photorelease of the caged glutamate. 
 
 
4.2.4 Voltammetry 
4-HPAA release was detected using carbon fiber microelectrodes 7µm in 
diameter and 30µm in length, constructed following a previously described method (21).  
A triangular waveform was applied to the carbon fiber microelectrode  beginning at -0.4 
V scanning up to +1.3 V and back down to -0.4 V at a scan rate of 300 V/sec and an 
update rate of 10 Hz.  The voltammetry data were collected versus a Ag/AgCl reference 
electrode.   
 
4.2.6 Shutter control/light exposure  
 A UNIBLITZ® optical shutter (Vincent Associates, Rochester, NY, USA), 
controlled by a controller designed and constructed by Kenneth Ratzlaff 
(Instrumentation Design Laboratory, University of Kansas), was triggered by the 
stimulus pulse and opened by a timed delay set by the control software.  The length of 
time the shutter remained open was also controlled by the software.   
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4.3 RESULTS  
 Monoamines, such as DA, play large roles in the brain as 
neurotransmitters.  DA is a neurotransmitter that participates in the signaling for 
physical movements (22).  There are many physiological conditions that deal with an 
altered level of DA, including Huntington’s disease, Parkinson’s disease, Tourette’s 
syndrome and Fragile X syndrome (4, 23-28).  The physical effects of Huntington’s 
disease include the physical degeneration of the brain, uncontrollable physical 
movements and dementia (4, 24).  The way in which DA transmission is altered in 
Huntington’s disease and other neurological disorders has been investigated through 
the use of cyclic voltammetry (4, 26, 29).  By using fast scan cyclic voltammetry and 
brain slices from disease model mice, extracellular concentrations of DA can be 
monitored (4, 30).  The response of the DA system can be measured in real time and 
changes caused to DA release and uptake by glutamate can be determined using 
FSCV paired with the photorelease of pHP-glu, avoiding toxicity issues and maintaining 
high temporal and spatial resolution (3, 11).   
 
4.3.1 Construction of Uncaging and FSCV Apparatus 
 Our original experimental design for releasing pHP-glu in brain slices was to 
utilize a Lambda DG-5 high speed wavelength switcher (Sutter Instruments, Novato, 
CA, USA) to expose the brain slice to select wavelengths of light through the 
microscope objective.  However, our setup would not allow light less than 340 nm 
through to the slice, and at 340 nm the intensity was low.  By HPLC analysis (Figure 2) 
we confirmed that we were not causing the photorelease of glutamate with this 
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experimental setup.  The photorelease of caged compounds generally occurs between 
250 and 360 nm (31), however, our original light source was not providing the intensity 
needed at 340 nm to photorelease the pHP-glu, thus a different light source was 
needed.   
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pHP-glu 
+ light
Caged 
Glutamate
A
b
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Figure 2.  HPLC data of caged glutamate samples (wavelength of 220 nm).  The top green trace was 
exposed to light from the original experimental setup, while the bottom trace was the unexposed caged 
glutamate sample, showing in the major peak in the chromatogram.  No difference in the intensity of the 
caged glutamate peak was seen. 
 
In order to achieve wavelengths around 300 nm with enough intensity to photo 
release the pHP-glu, a 100 W Oriel mercury (Hg) lamp (Newport Corporation, Irving, 
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CA, USA) was used for UV light emission.  To control the length of time the samples 
were exposed to light, a shutter was positioned in front of the focusing lens on the Hg 
light source.  The shutter is controlled by software produced in the Instrument Design 
Laboratory at the University of Kansas and can be programmed to remain open for a 
desired length of time.  The stimulus pulse used to cause DA release can also be paired 
to the shutter, signaling it to open based on the software parameters.  The light output 
was focused to an intense dot and a fiber optic was positioned such that the light was 
successfully transmitted to the desired location. The fiber optic was held by an 
adjustable holder so that’s its position in front of the light source could be easily 
adjusted to give the most intense output through the fiber optic (Figure 3).  The light 
source design was based on work previously done by Karl Kandler (31). 
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Figure 3.  Mercury lamp with the shutter and fiber optic set up in front of the lens.   
 
 
The light system then needed to be paired to the apparatus used for brain slice 
experiments.  Figure 4 depicts the resulting setup of the uncaging apparatus which is 
paired with a FSCV setup.  The fiber optic was connected to a micromanipulator so that 
the position of the fiber relative to both the carbon fiber microelectrode and surface of 
the brain slice could easily be adjusted and moved.  Micromanipulators allow us to 
easily move the working and stimulating electrodes to various locations in the brain slice 
and thus allow us to collect multiple data points from the same slice.  By using a 
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micromanipulator with the fiber optic, it becomes possible to move the location of the 
light exposure to various positions throughout the brain slice as we move our stimulating 
and working electrodes.  Since the fiber optic produces such a small area of light, it 
should be possible to move the electrode to a new location in the brain slice and collect 
more data points from unexposed locations.    
 
 
 
Figure 4. Experimental design for the uncaging of glutamate in slices.    
 
We then had to verify release of caged glutamate by exposure to light from the 
new light source and evaluate how stable the samples were when allowed exposure to 
ambient light.  Samples of the pHP-glu were also placed out in the room exposed to 
both sunlight and the room lights in order to determine if the ambient light would cause 
significant amounts of uncaging of the pHP-glu.  After 10 minutes of expose the sample 
was evaluated using HPLC and no increase in the presence of the 4-HPAA byproduct 
was seen.  To ensure glutamate release using the Hg lamp, samples of the pHP-glu 
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solution were exposed to light from the Hg lamp and analyzed using HPLC.  Figure 5 
shows that we were able to successfully uncage glutamate using our light source.  A 
sample containing the major release byproduct (Green) was evaluated by HPLC to 
confirm the peak placement.  The unexposed sample (Blue) produced a large peak at a 
later time than the peak caused by the 4-HPAA standard.  After light exposure (Red) the 
intensity of the caged glutamate peak greatly diminished, while a peak at the same 
retention time as the byproduct peak was detected confirming the release of 4-HPAA 
and indicating the release of glutamate.  There were also other smaller peaks that were 
detected in the sample exposed to light from the mercury lamp.  These other peaks 
correspond to other minor byproducts caused by photorelease (peaks were confirmed 
by collecting chromatograms of the other byproducts, data not shown).   
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Figure 5.  Confirmation of uncaging caused by light exposure from the mercury lamp.  The blue trace 
shows the original sample with no 4-HPAA byproduct peak, which is the major byproduct from the 
uncaging.  The green trace shows the 4-HPAA standard and the red trace shows the sample exposed to 
light from the mercury lamp with a major peak overlapping the 4-HPAA standard with other minor 
byproduct peaks detected as well.  (Wavelength = 220 nm) 
 
4.3.2 Detection of the Photorelease Byproduct  
The amount of caged compound released is dependent on the concentration of 
the caged sample, the duration and intensity of the light exposure and the area of the 
light spot (31).  The heterogeneity of the striatum paired with repositioning of the fiber 
optic caused a need for a method to determine how much glutamate was released.  
Work is being conducted in our laboratory to develop a means of quantifying the release 
of caged glutamate by using FSCV to detect the 4-HPAA byproduct.   
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4.4 DISCUSSION 
 Various caged compounds have been used in biological systems over the last 
several decades to elucidate the immediate responses to compounds one they are 
photoreleased (32-33).  The utilization of p-hydroxyphenacyl protecting group has 
provided investigators with a photoreleaseing group that releases on a much faster time 
scale (2).  The faster response time of the pHP photoreleasing group makes it a 
valuable compound for evaluation of neurotransmission.   
 Glutamate bound to the pHP photoprotecting group has been utilized in the 
evaluation of neuronal responses in brain slices using whole cell patch clamp 
recordings (17, 31).  Since FSCV allows us to detect real time alterations in 
neurotransmitter release and uptake, combining photoreleasing compounds with FSCV 
opens up opportunities to evaluate the immediate effect of compounds on the release or 
uptake of the targeted neurotransmitter, in our case DA.  There has been work done 
utilizing caged DA with FSCV in brain slices (3); however, having other compounds that 
cause changes to the DA system will allow greater understanding of how the DA system 
is functioning.   
 We have shown that our experimental setup works to release pHP-glu in solution 
and that we can detect the release of the byproduct to verify the amount of glutamate 
released.  The use of this instrumentation will allow FSCV to be paired with 
photoreleasing compounds in slices for the investigation of the immediate response of 
the DA system in various locations of the brain and also in animal models of different 
neurological disease states.  The information obtained by utilizing caged compounds in 
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FSCV brain slice experiments will elucidate important information that may provide 
therapeutic targets.    
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4.5 CONCLUDING REMARKS 
 To establish a means of utilizing caged compounds in FSCV brain slice 
experiments, a mercury lamp setup with a micromanipulator controlled fiber optic was 
constructed.  Our original experimental design was proven to be flawed after light 
exposure and a failure to cause any photorelease of the pHP-glu.  During the study the 
release of pHP-glu by the mercury lamp setup was confirmed using HPLC analysis.  To 
determine if the pHP-glu in aCSF solution was stable in ambient light, a sample was 
exposed to room lighting and analyzed using HPCL, confirming that the sample was not 
photoreleasing due to exposure to ambient light.  The ability to oxidize 4-HPAA, the 
photoreleasing byproduct, has also been shown by work in our laboratory.  Using this 
method for the release and detection of compound effects on DA release will provide 
great insight into the dopaminergic system in different animal models.   
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CHAPTER 5 
 
SUMMARY OF FINDINGS AND FUTURE DIRECTIONS 
 
 Understanding the alterations caused to the dopaminergic system in disease 
states involving alterations in cognition and motor function will aid in the development of 
therapies to help improve the quality of life for sufferers.  This work has presented 
insight into the changes to the dopamine (DA) system that occur in both a genetic 
neurological disorder and in neurological problems cause by drug administration.  A 
method to evaluate the real time DA response to photoreleased neurotransmitters has 
also been presented.  The major findings of each project and potential future research 
ideas are presented below.   
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5.1 FRAGILE X SYNDROME 
5.1.1 Major Findings 
 Our behavioral analysis of the Fmr1 KO mice using the force plate actometer 
showed a significant difference in the locomotor activity of the KO mice compared to the 
WT mice, which agrees with earlier findings (1-2).  The mice that received injections of 
amphetamine showed similar locomotor activity, however, the Fmr1 KO mice were less 
sensitive to amphetamine in their focused stereotypy behavioral response.  At the 10 
mg/kg dose, a dose in the range known for causing focused stereotypy (3-4), the KO 
mice showed a significant lesser amount of time spent in experiencing focused 
stereotypy.   
   By evaluation of DA release and uptake using brain slices from the Fmr1 KO 
and WT mice, we have shown that as the mice age, a significant difference in striatal 
DA release and uptake was seen in the 15 week and 20 week old mice, but no 
difference was found in the younger 10 week old mice.  The mice that had undergone 
the behavioral analysis were in the 15 week group and the altered behavioral response 
may be explained by the impaired release.  DA content analysis was done using HPLC 
to determine if the altered release was due to an alteration in the amount of DA present 
in the striatum.  No differences in the concentration of DA in striatal homogenate were 
found.   
By exposing the slices to increasing concentrations of AMPH and in another 
experiment GBR12909, we found that the affinity of AMPH and GBR for DAT is the 
same in both the KO and WT mice.  Our results are consistent with the concept that 
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release impairments contribute to the altered behavioral response to AMPH.  However, 
differences in the number of DAT protein molecules may also contribute. 
 We have also shown that there is no significant difference in the DA response 
after slice exposure to MPEP, an antagonist for MGluR5 receptors which are 
hypothesized to be hyperactive in Fragile X syndrome.  The response to quinpirole, a 
selective D2 agonist, was also unchanged between the KO and WT mice, indicating 
proper D2 function in the KO mice.  Data from mobilizing DA reserve pools by use of 
cocaine, after stimulated DA release was eliminated by D2 activation with quinpirole, 
indicated that reserve pools are unaltered in Fragile X syndrome.   
  
 
5.1.2 Future Research Ideas 
 The levels of DAT are known to decrease with aging (5) and may decline more 
rapidly in FXS leading to alterations in the uptake of DA after stimulated release.  In 
order to assess the amount of DAT present in the striatum of the Fmr1 KO mice 
compared to the WT mice, Western Blot analysis can be used. 
DA release was impaired in the KO mice yet the total DA content was unchanged 
indicating a problem with the mechanism of release or the filling of vesicles.  Since DA 
release is dependent on Ca2+ entry and studies have shown alterations in Ca2+ 
sensitivity in neurological disorders (6), a study evaluating the DA response to different 
concentrations of Ca2+ in the perfusion aCSF could lead to insight into the role of Ca2+ in 
the altered DA release seen in FXS.  A study using Fura-2 would also provide a means 
to quantify calcium levels in brain slices (7-8). 
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 One study has shown a potential utility of dosing Drosophila flies with small 
molecules to recover some of the phenotypical characteristics in FXS model Drosophila 
flies (9).  One of the small molecules used was MPEP (2-Methyl-6-
(phenylethynyl)pyridine).  Fmr1 KO mice could be given MPEP in their food over time 
and the DA release and uptake studies done in brain slices repeated to evaluate if the 
administration of MPEP helps to recover the impaired DA release that we have shown.      
.   
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5.2 “CHEMOBRAIN” 
5.2.1 Summary of Findings 
 After dosing male Wistar rats with carboplatin weekly for four weeks, stimulated 
DA release and uptake was detected in slices.  Data were collected in each of the four 
regions in the striatum.  ANOVA analysis revealed a significant dose effect in the peak 
stimulated DA release as well as in the [DA]p.  However, Vmax showed no significant 
effect over the doses.  We also found no significant difference between the 
measurements taken in the different quadrants within a dose, showing that carboplatin 
had a generalized effect on DA release in all four quadrants of the striatum.  DA efflux 
was also measured by inhibition of DA synthesis with αMPT and efflux caused by 
AMPH.  There was no significant difference seen in the amount of DA efflux in the 
carboplatin treated rats.       
 
  
5.2.2 Future Research Ideas 
 This work was done to collect preliminary data and confirm our hypothesis that 
the DA system undergoes alterations due to chemotherapy and contributes to the 
problem known as “chemobrain.”  There are many different prospective experiments 
that could advance the project and further our understanding of the neurological 
problems occurring during and after chemotherapy.   
 The experiment presented here should be repeated to confirm our findings as 
well as to provide more samples to use in collecting DA content data by HPLC since we 
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did not have enough samples to get statistically relevant data after this first study.  It 
would also be beneficial to verify the reserve pool data.   
 It would also be advantageous to evaluate neurotransmitter release in other 
regions of the brain that are associated with cognition.  One such location is the 
hippocampus, which may provide further insight to the chemobrain problem. 
 Various other chemotherapeutic drugs have been indicated in “Chemobrain” (10-
13), especially in cases of breast cancer treatment.  Since chemobrain is a post 
chemotherapy complaint most commonly from women who have undergone treatment 
for breast cancer, tailoring the drugs to match those most commonly used in breast 
cancer treatment would provide further insights into treatment of the cognitive issues 
experience by the reporting women.   
 After using male rats to establish the effects of just the chemo drugs on DA 
release, beginning to dose female rats will introduce hormonal effects, which can play a 
part in the experiences of the women reporting cognitive issues after therapy.   
 All of the data collected in this project will assist in the development of ways to 
treat the cognitive decline experienced by cancer patients.  There have been successes 
with the use of methylphenidate and erythropoietin (14-17); however this work would 
open up more opportunities to find other, more suitable treatments.    
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5.3 CAGED COMPOUNDS 
5.3.1 Summary of Findings 
 While caged compounds have been used in brain slices (18-20), utilizing caged 
compounds paired with FSCV opens up many opportunities to evaluate DA responses 
in real time to the photorelease of different compounds.  We have shown that our 
instrumentation can successfully release glutamate bound to the p-hydroxyphenacyl 
photoprotecting group.   
 
5.3.2  Future Research Ideas 
 The effects of photoreleasing pHP-glu on DA release and uptake in brain slices, 
while quantifying the amount of 4-HPA byproduct is produced by the light exposure to 
quantify the amount of glutamate released.  After characterizing the immediate effects 
of releasing glutamate on DA release and uptake, GABA could be used since it has 
already been synthesized with the pHP protecting group.   
 Applying the use of caged compounds in brain slices of neurological disease 
states could also provide valuable information about the response to glutamate and 
GABA.  It would be especially helpful in evaluation of the response of the DA system to 
glutamate and GABA photorelease in FXS since it is hypothesized that glutamate may 
play a role in the phenotypical problems associated with the syndrome.   
 The synthesis of other compounds utilizing the pHP “cage” would also allow for 
many other experiments to be performed to investigate the real time DA response.   
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